<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.3" xml:lang="EN" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JACS Au</journal-id><journal-id journal-id-type="iso-abbrev">JACS Au</journal-id><journal-id journal-id-type="publisher-id">au</journal-id><journal-id journal-id-type="coden">jaaucr</journal-id><journal-title-group><journal-title>JACS Au</journal-title></journal-title-group><issn pub-type="epub">2691-3704</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862947</article-id><article-id pub-id-type="doi">10.1021/jacsau.4c01020</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Metabolic PCTA-Based
Shift Reagents for the Detection
of Extracellular Lactate Using CEST MRI</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Chiaffarelli</surname><given-names>Remy</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Cruz</surname><given-names>Pedro F.</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Cotton</surname><given-names>Jonathan</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Kelm</surname><given-names>Tjark</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Lee</surname><given-names>Slade</given-names></name><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Ghaderian</surname><given-names>Mohammad</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Zimmermann</surname><given-names>Max</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Geraldes</surname><given-names>Carlos F. G. C.</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref><xref rid="aff6" ref-type="aff">#</xref><xref rid="aff7" ref-type="aff">&#x000b6;</xref></contrib><contrib contrib-type="author" id="ath9"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9390-046X</contrib-id><name><surname>Jurek</surname><given-names>Paul</given-names></name><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath10"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0171-0261</contrib-id><name><surname>Martins</surname><given-names>Andr&#x000e9; F.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Werner
Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, <institution>University Hospital T&#x000fc;bingen</institution>, T&#x000fc;bingen 72076, <country>Germany</country></aff><aff id="aff2"><label>&#x02021;</label>Cluster
of Excellence iFIT (EXC 2180) &#x0201c;Image-Guided and Functionally
Instructed Tumor Therapies&#x0201d;, <institution>University
of T&#x000fc;bingen</institution>, T&#x000fc;bingen 72076, <country>Germany</country></aff><aff id="aff3"><label>&#x000a7;</label><institution>German
Cancer Consortium (DKTK), Partner Site T&#x000fc;bingen, German Cancer
Research Center (DKFZ)</institution>, Im Neuenheimer Feld 280, Heidelberg 69120, <country>Germany</country></aff><aff id="aff4"><label>&#x02225;</label>Coimbra
Chemistry Center-Institute of Molecular Sciences (CQC-IMS), Faculty
of Science and Technology, <institution>University of
Coimbra</institution>, Coimbra 3004-535, <country>Portugal</country></aff><aff id="aff5"><label>&#x022a5;</label><institution>Macrocyclics,
Inc.</institution>, Plano, Texas 75074, <country>United States</country></aff><aff id="aff6"><label>#</label>CIBIT&#x02014;Coimbra
Institute for Biomedical Imaging and Translational Research, <institution>University of Coimbra</institution>, Coimbra 3000-548, <country>Portugal</country></aff><aff id="aff7"><label>&#x000b6;</label>Department
of Life Sciences, <institution>University of Coimbra</institution>, Coimbra 3000-456, <country>Portugal</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>andre.martins@med.uni-tuebingen.de</email>.</corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>02</month><year>2025</year></pub-date><pub-date pub-type="collection"><day>24</day><month>02</month><year>2025</year></pub-date><volume>5</volume><issue>2</issue><fpage>779</fpage><lpage>790</lpage><history><date date-type="received"><day>28</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>16</day><month>01</month><year>2025</year></date><date date-type="rev-recd"><day>15</day><month>01</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="au4c01020_0006" id="ab-tgr1"/></p><p>Lactate is a key
metabolic driver in oncology and immunology.
Even
in the presence of physiological oxygen levels, most cancer cells
upregulate anaerobic glycolysis, resulting in abnormal lactate production
and accumulation in the tumor microenvironment. The development of
more effective, sensitive, and safe probes for detecting extracellular
lactate holds the potential to significantly impact cancer metabolic
profiling and staging significantly. Macrocyclic-based PARACEST agents
have been reported to act as shift reagents (SRs) and detect extracellular
lactate via chemical exchange saturation transfer (CEST) MRI. Here,
we introduce a new family of SRs based on the PCTA ligand, an inherently
stable and kinetically inert group of molecules with the potential
for (pre)clinical translation. We observed that Yb-PCTA and Eu-PCTA
can significantly shift lactate &#x02013;OH signals in the CEST spectra. <italic>In vitro</italic>, CEST MRI experiments proved that imaging extracellular
lactate specifically with these complexes is feasible even in the
presence of competing small metabolites in blood and in the tumor
microenvironment. <italic>In vivo</italic> preclinical imaging showed
that Yb-PCTA can be safely administered intravenously in mice to detect
extracellular lactate noninvasively. This work contributes to the
field of precision imaging in medicine and provides evidence that
the PCTA-ligand is a valuable scaffold for developing molecular and
metabolic imaging sensors.</p></abstract><kwd-group><kwd>lactate</kwd><kwd>PARACEST</kwd><kwd>ytterbium</kwd><kwd>europium</kwd><kwd>CEST MRI</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>Alexander von Humboldt-Stiftung</institution><institution-id institution-id-type="doi">10.13039/100005156</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Deutschen Konsortium f&#x000c3;&#x000bc;r Translationale Krebsforschung</institution><institution-id institution-id-type="doi">10.13039/501100012353</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Eberhard Karls Universit&#x000c3;&#x000a4;t T&#x000c3;&#x000bc;bingen</institution><institution-id institution-id-type="doi">10.13039/501100002345</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Funda&#x000c3;&#x000a7;&#x000c3;&#x000a3;o para a Ci&#x000c3;&#x000aa;ncia e a Tecnologia</institution><institution-id institution-id-type="doi">10.13039/501100001871</institution-id></institution-wrap></funding-source><award-id>UIDP/00313/2020</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Funda&#x000c3;&#x000a7;&#x000c3;&#x000a3;o para a Ci&#x000c3;&#x000aa;ncia e a Tecnologia</institution><institution-id institution-id-type="doi">10.13039/501100001871</institution-id></institution-wrap></funding-source><award-id>UID/QUI/00313/2020</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Funda&#x000c3;&#x000a7;&#x000c3;&#x000a3;o para a Ci&#x000c3;&#x000aa;ncia e a Tecnologia</institution><institution-id institution-id-type="doi">10.13039/501100001871</institution-id></institution-wrap></funding-source><award-id>POCI-01-0145-FEDER-027996</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Deutsche Forschungsgemeinschaft</institution><institution-id institution-id-type="doi">10.13039/501100001659</institution-id></institution-wrap></funding-source><award-id>EXC 2180</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Deutsche Forschungsgemeinschaft</institution><institution-id institution-id-type="doi">10.13039/501100001659</institution-id></institution-wrap></funding-source><award-id>527345502</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Deutsche Forschungsgemeinschaft</institution><institution-id institution-id-type="doi">10.13039/501100001659</institution-id></institution-wrap></funding-source><award-id>516238665</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Werner Siemens-Stiftung</institution><institution-id institution-id-type="doi">10.13039/100016964</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>au4c01020</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>au4c01020</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Metabolic imaging, the noninvasive visualization
of metabolite
distribution within living organisms, is essential for understanding
disease processes and assessing treatment responses. It enables the
early detection, characterization, and monitoring of relevant diseases,
e.g., in oncology and neurology, and therefore holds paramount significance
in medicine and biomedical research. A key aspect of metabolic imaging
is that it allows monitoring of the dynamic behavior of cells and
tissues, offering the potential to identify abnormal metabolic patterns
associated with disease states. For example, cancer cells overproduce
lactate, even in the presence of high oxygen and glucose levels, a
phenomenon called the Warburg effect. Most of the lactate produced
by cancer cells builds up in the extracellular environment, affecting
the tumor and the homeostasis of the surrounding tissues.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> Detecting the lactate buildup in tissues is thus
critical as it translates to a precise measure of cancer metabolic
activity and may provide a direct readout of cancer staging.</p><p>Modern imaging technologies offer substantial promise for assessing
cancer metabolic activity and tumor staging. Magnetic resonance spectroscopy,
aided by hyperpolarized <sup>13</sup>C-labeled substrates like pyruvate<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> and fumarate<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> or deuterated
metabolites like glucose and acetate,<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> provides
invaluable information regarding enzymatic activity in tumors related
to staging and therapy response. These methods, however, lack spatial
resolution and cannot distinguish between intra- and extracellular
metabolic processes, preventing the accurate quantification of extracellular
lactate produced by the tissues. The chemical shift between lactate
hydroxyl and water protons allows the detection of lactate with chemical
exchange saturation transfer (CEST) techniques;<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref6">6</xref></sup> however,
it does not aid in the discrimination between extra- and intracellular
lactate. The water signal obscures the slight chemical shift of free
lactate (&#x0003c;1 ppm), hampering the quantification of small lactate
concentrations. Hence, a method for noninvasively imaging extracellular
lactate produced by the cancer cells is of utmost importance to better
understand metabolic dynamics and compartmentalization.</p><p>Recently,
a family of shift reagents (SRs) has demonstrated remarkable
capabilities in selectively detecting extracellular lactate using
CEST. These CEST SRs consist of stable inorganic complexes formed
by the complexation of lanthanide ions with DOTA-type macrocycles.
A Yb<sup>3+</sup> complex based on a derivative of DO3A, Yb-MBDO3AM,
was reported to bind to lactate at different concentrations.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> A simplified version of these SRs utilized the
Eu-DO3A complex, which coordinates with lactate by displacing the
two water molecules directly bound to the inner sphere of the lanthanide.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> This specific interaction creates a ternary complex
with lactate, allowing for the precise detection of the lactate &#x02013;OH
group, effectively shifting it away from the bulk water signal. When
coadministered in the ternary complex with lactate, Eu-DO3A could
readily detect extracellular lactate excreted in the bladder of a
healthy mouse. Despite detecting the intact Eu-DO3A form in the urine,
lanthanide complexes formed with DO3A show a lower kinetic inertness
than most octacoordinated Ln-DOTA complexes. Kinetic inertness is
a crucial parameter when designing medical imaging inorganic contrast
agents (CAs) directed to clinical translational applications as the
release of lanthanide ions (e.g., Gd<sup>3+</sup>) may lead to severe
physiological complications associated with nephrogenic systemic fibrosis
(NSF) in patients with renal impairment.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> In this pursuit, the pyclen-based PCTA ligand proved to be an important
alternative to cyclen-based DOTA-type macrocycles due to its high
thermodynamic stability (log <italic>K</italic><sub>ML</sub> = 18.15&#x02013;20.63
for Ce&#x02013;Yb) and kinetic inertness (<italic>t</italic><sub>1/2</sub> in the range of hours) similar to those of Ln-DOTA complexes.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> Like Ln-DO3A complexes, Ln-PCTA complexes generally
show higher hydration (<italic>q</italic> = 2) and faster water exchange
rates (<italic>k</italic><sub>ex</sub>) than Ln-DOTA complexes due
to their increased rigidity akin to Ln-DO3A.<sup><xref ref-type="bibr" rid="ref11">11</xref>&#x02212;<xref ref-type="bibr" rid="ref15">15</xref></sup> The heptadentate PCTA ligand forms Ln<sup>3+</sup> complexes that are highly suitable for safe translational applications,
despite the increased hydration of Ln-PCTA complexes, which allows
other biogenic molecules to replace the water molecules in the coordination
sphere. In 2022, the FDA approved the Gd-PCTA-based complex (gadopiclenol)
as a new MRI CA. This CA shows improved <italic>T</italic><sub>1</sub> MR contrast properties compared to traditional Gd-based MRI CAs
with octadentate ligands.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup></p><p>Here,
we describe the development of a new generation of SRs based
on Ln-PCTA for the selective detection of extracellular lactate by
CEST MRI. For this purpose, we selected Ln<sup>3+</sup> ions that
have a minor impact on the <italic>T</italic><sub>1</sub> relaxation
of water protons in the concentration ranges relevant for CEST MRI:
Eu<sup>3+</sup>, Yb<sup>3+</sup>, and Pr<sup>3+</sup>.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> The interaction between Ln<sup>3+</sup>-based
PCTA complexes (Yb-PCTA, Eu-PCTA, and Pr-PCTA) and lactate was characterized
by using high-resolution nuclear magnetic resonance (NMR), revealing
the formation of lactate-Ln-PCTA ternary complexes. The CEST effect
of these complexes was quantified <italic>in vitro</italic> at 7T,
demonstrating a specific signal for lactate. Additionally, binding
affinity values indicated a weak interaction, suggesting that lactate
was not significantly depleted from the bloodstream when these SRs
were used for <italic>in vivo</italic> imaging. <italic>In vitro</italic> cytotoxicity assessment validated the safety and feasibility of
SRs for <italic>in vivo</italic> imaging. A preclinical animal study
using Yb-PCTA showed the safe detection of the lactate-Yb-PCTA ternary
complex in the bladder, emphasizing the translational potential of
this approach. Moreover, the shiftCEST approach was validated in a
tumor-bearing animal model, further showcasing its ability to monitor
lactate metabolism and tumor microenvironment (TME) characteristics.
This work highlights the capability of lanthanide-based PCTA complexes
and CEST MRI for metabolic imaging applications, offering a new tool
for profiling various cancer cell lines and the associated TME.</p></sec><sec id="sec2"><title>Results
and Discussion</title><p>In this study, we investigated
whether a new generation of SRs
based on Ln-PCTA could detect extracellular lactate and provide selective
detection of extracellular lactate by CEST MRI <italic>in vitro</italic> and preclinically. We prepared several solutions containing Ln-complexes
(Ln: Eu<sup>3+</sup>, Yb<sup>3+</sup>, and Pr<sup>3+</sup>) to explore
the potential formation of ternary complexes between Ln-PCTA and lactate.
Phantom imaging experiments were performed in serum to mimic physiological
conditions and at pH 6 and 7 to more closely resemble acidic conditions
often found in the TME, where lactate accumulates.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> Eu<sup>3+</sup>, Yb<sup>3+</sup>, and Pr<sup>3+</sup> were
selected based on the expected induced chemical shifts resulting from
their large magnetic moments<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> and their
limited impact on the longitudinal and transversal relaxation of water
protons (<italic>r</italic><sub>1</sub>, <italic>r</italic><sub>2</sub>) compared to other Ln<sup>3+</sup> such as Gd<sup>3+</sup>. The
PCTA complexes employed in the study were synthesized as described
in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Supporting Information</ext-link>. As depicted
in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>, a ternary
complex can be formed between the Ln-PCTA complexes and lactate by
replacing at least one of its two inner-sphere water molecules, as
observed before between Ln-DO3A-type complexes with lactate and other
&#x003b1;-hydroxy-carboxylates.<sup><xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref20">20</xref></sup> To determine if the
Ln-PCTA complexes are selective for the extracellular fraction of
lactate, we tested whether Ln-PCTA complexes could cross cellular
membranes using a permeability artificial membrane penetration assay
(PAMPA).<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> The results showed only trace
levels of Ln-PCTA complexes in the acceptor compartment after 21 h
(9.5 &#x000b1; 0.9% of the theoretical equilibrium concentration) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Figure S1A</ext-link>). Additionally, in a cell experiment,
the growing medium of cells incubated with Yb-PCTA or a known extracellular
CA (Gd-DOTA, Gadovist) was analyzed with bulk magnetic susceptibility
(BMS) NMR measurments to determine the concentration of the Ln<sup>3+</sup> complexes after 2 h of incubation and quantify the uptaken
fraction. No significant difference was found in the concentration
of wells containing cells and control wells, indicating that these
complexes primarily remain extracellular and are imported in the intracellular
compartment only to a minor extent (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Figure S1B</ext-link>). This makes them ideal for detecting extracellular lactate, with
negligible intracellular interference in the timespan that could be
useful for <italic>in vivo</italic> imaging (15&#x02013;30 min).</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Illustrative
schematic of the formation of a ternary complex lactate-Yb-PCTA.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="au4c01020_0001" id="gr1" position="float"/></fig><p>In an aqueous solution, DOTA-type complexes show
the presence of
twisted square antiprismatic (TSAP) and square antiprismatic (SAP)
diastereoisomeric pairs of enantiomers, which result from the combination
of the two square [3,3,3,3] conformations of the cyclen macrocyclic
ring, in which the four ethylenediamine N&#x02013;C&#x02013;C&#x02013;N
bridges adopt the identical gauche conformations of opposite helicities,
(&#x003b4;&#x003b4;&#x003b4;&#x003b4;) or (&#x003bb;&#x003bb;&#x003bb;&#x003bb;),
with the two possible orientations of the acetate arms attached to
the macrocyclic nitrogen atoms, &#x0039b; (clockwise) and &#x00394; (counterclockwise).<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> Eu- and Yb-DO3A were reported to show a preferred
SAP structure, with the metal-coordinated lactate having the OH group
in an apical position and showing highly shifted CEST peaks of approximately
45 and 150 ppm, respectively.<sup><xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref20">20</xref></sup> A less favored TSAP
structure produced a smaller shift (16 ppm) for the CEST peak of Eu-DO3A-lactate
with the OH group in a more equatorial position.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> However, in the case of Ln-PCTA, the rigidity of the pyridine
group in the pyclen ring makes it impossible to adopt the [3,3,3,3]
conformation. Instead, it adopts a [4,2,4,2] conformation bisected
by a mirror plane with the nitrogen atoms located in the center of
each side of the ring and the three ethylenediamine N&#x02013;C&#x02013;C&#x02013;N
bridges having (&#x003b4;&#x003bb;&#x003b4;&#x003bb;) conformations. The Ln-PCTA
complexes feature three acetate arms and can adopt twisted snub disphenoid
(TSD) coordination geometries. A 3D structure in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B shows the proposed interaction
between Ln-PCTAs and lactate. These geometries exhibit both (&#x003b4;&#x003bb;&#x003b4;&#x003bb;)&#x0039b;
and (&#x003b4;&#x003bb;&#x003b4;&#x003bb;)&#x00394;<italic>o</italic>rientations,
and due to the rigidity of the pyridine unit, the four nitrogen atoms
are not coplanar. Consequently, the TSAP and SAP conformations typical
of DOTA-like complexes are unattainable.<sup><xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24</xref></sup> Taking this information into account, we determined the diastereoisomers
of Ln-PCTA-lactate in solution using high-resolution <sup>1</sup>H
NMR spectra of Yb-, Eu-, and Pr-PCTA in the absence/presence of 2
equiv of lactate at various temperatures and pH values. The Ln-PCTA
complexes are highly fluxional at high temperatures, with a fast exchange
in the NMR timescale at 90 &#x000b0;C, between the dominant TSD (&#x003b4;&#x003bb;&#x003b4;&#x003bb;)&#x0039b;
isomer (10 resonances, as expected from the structure) with the very
low populated (&#x0003c;10%) TSD (&#x003b4;&#x003bb;&#x003b4;&#x003bb;)&#x00394;
isomer, leading to extensive broadening of most resonances at 25 &#x000b0;C.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> In the presence of lactate, the <sup>1</sup>H NMR spectra at 90 &#x000b0;C showed two extra signals (2.01 and 5.42
ppm for Yb-PCTA-lactate) corresponding to the CH<sub>3</sub> and CH
groups of coordinated lactate in the Ln-PCTA-lactate ternary complexes
in solution, which displayed only the TSD (&#x003b4;&#x003bb;&#x003b4;&#x003bb;)&#x0039b;
isomer. Again, this isomer is in fast exchange with the very minor
(&#x003b4;&#x003bb;&#x003b4;&#x003bb;)&#x00394; isomer, as reflected in an extensive
broadening of most resonances at lower temperatures (<xref rid="fig2" ref-type="fig">Figures <xref rid="fig2" ref-type="fig">2</xref></xref>A, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">S2&#x02013;S4</ext-link>) and the presence of exchange cross-peaks in the EXSY spectrum of
Eu-PCTA different from those of the COSY spectrum (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Figure S5</ext-link>).<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> The resonances of
bound lactate exhibit some broadening at 90 &#x000b0;C compared to the
free lactate resonances. However, as temperatures decrease, they gradually
broaden until disappearing entirely at &#x0223c;0 &#x000b0;C, suggesting
a fast-to-intermediate exchange regime in their binding to Ln-PCTA
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Figures S4 and S5</ext-link>). This suggests a relatively
weak interaction between lactate and the Ln-PCTA complexes, a finding
supported by CEST titrations (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Figure S6</ext-link> and <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). This
weak interaction may be attributed to the TSD conformation of the
complex, where the four nitrogen atoms of the pyclen ring do not align
in the same plane&#x02014;two are positioned above and two below the
median plane. Consequently, the three Ln-bound carboxylate oxygens
are located slightly off the single plane. This distortion of the
two available lactate-binding positions within Ln-PCTA could lead
to steric hindrance in lactate binding. Additionally, a recent report
shows how a 100-fold excess of lactate induces a 25% decrease of the <italic>r</italic><sub>1</sub> of Gd-PCTA, confirming the meager binding.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> While the axial CH<sub>2</sub> protons from
the macrocyclic ring in PCTA complexes showed less shifted resonances
compared to the corresponding DO3A complexes, typical of TSAP structures,
we observed shifts for all the proton resonances and broadening of
some of them when lactate was bound. Hence, we anticipated a reasonable
&#x02013;OH CEST shift in the CEST spectra for the lactate &#x02013;OH
group as it exchanges with the surrounding bulk water. However, for
efficient CEST imaging, the <italic>T</italic><sub>1</sub> relaxation
times of the exchanging system must be sufficiently long to ensure
that the CEST signal does not decrease rapidly during the acquisition.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> We have determined <italic>T</italic><sub>1</sub> values and the corresponding <italic>r</italic><sub>1</sub> relaxivity,
a key governing parameter for CEST detection, in blood serum at 37
&#x000b0;C. We measured <italic>r</italic><sub>1</sub> values of 0.009
mM<sup>&#x02013;1</sup>&#x000b7;s<sup>&#x02013;1</sup> for Yb-PCTA, 0.003
mM<sup>&#x02013;1</sup>&#x000b7;s<sup>&#x02013;1</sup> for Eu-PCTA, and
0.007 for mM<sup>&#x02013;1</sup>&#x000b7;s<sup>&#x02013;1</sup> Pr-PCTA
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Figure S7</ext-link>). Therefore, the impact of longitudinal
relaxation on CEST detection can be considered negligible.<sup><xref ref-type="bibr" rid="ref27">27</xref>,<xref ref-type="bibr" rid="ref28">28</xref></sup></p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>(A) <sup>1</sup>H NMR spectra of a solution containing 3 mM Yb-PCTA
(black line) and 2:1 lactate-Yb-PCTA mixture (orange line), acquired
at 400 MHz, 363 K, pH 7.1. (B) 3D schematic of the interaction lactate-Ln-PCTA.
(C,D) z-spectra (C) and MTRasym % (D) plot of 50 mM Yb- and Eu-PCTA
in HEPES buffer with 50 mM lactate, acquired at 7T MR after presaturation
pulses of 16 &#x003bc;T and 5 s, at 298 K, pH 6.7. &#x0201c;No lactate&#x02033;:
spectrum of Eu-PCTA without lactate. CEST spectra were fitted to Lorentzian-line
shapes using a two-pool model (lactate-Ln-PCTA and water). (E) z-spectra
of 1:1 20 mM lactate-Pr-PCTA or 20 mM lactate, acquired with 5 s 16
&#x003bc;T saturation pulses, pH 6. (F) z-spectra of 1:1 40 mM lactate-Pr-PCTA
or 40 mM lactate, acquired in a narrower spectral bandwidth with 5
s 20 &#x003bc;T saturation pulses, pH 6.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="au4c01020_0002" id="gr2" position="float"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Binding and Exchange Rates of Lactate&#x000b7;SRs<xref rid="t1fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center" char=".">pH</th><th style="border:none;" align="center"><italic>K</italic><sub>A</sub> (M<sup>&#x02013;1</sup>)</th><th style="border:none;" align="center"><italic>k</italic><sub>ex</sub> (s<sup>&#x02013;1</sup>)</th></tr></thead><tbody><tr><td style="border:none;" align="left">Yb-PCTA</td><td style="border:none;" align="char" char=".">6</td><td style="border:none;" align="left">20&#x000a0;&#x000b1;&#x000a0;2</td><td style="border:none;" align="left">1270&#x000a0;&#x000b1;&#x000a0;35</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">7</td><td style="border:none;" align="left">11&#x000a0;&#x000b1;&#x000a0;1</td><td style="border:none;" align="left">1770&#x000a0;&#x000b1;&#x000a0;40</td></tr><tr><td style="border:none;" align="left">Eu-PCTA</td><td style="border:none;" align="char" char=".">6</td><td style="border:none;" align="left">100&#x000a0;&#x000b1;&#x000a0;10</td><td style="border:none;" align="left">1810&#x000a0;&#x000b1;&#x000a0;45</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">7</td><td style="border:none;" align="left">25&#x000a0;&#x000b1;&#x000a0;3</td><td style="border:none;" align="left">2820&#x000a0;&#x000b1;&#x000a0;90</td></tr><tr><td style="border:none;" align="left">Yb-DO3A</td><td style="border:none;" align="char" char=".">6.5</td><td style="border:none;" align="left">N/A</td><td style="border:none;" align="left">1900<xref rid="t1fn2" ref-type="table-fn">b</xref></td></tr><tr><td style="border:none;" align="left">Eu-DO3A</td><td style="border:none;" align="char" char=".">6</td><td style="border:none;" align="left">45<xref rid="t1fn4" ref-type="table-fn">d</xref></td><td style="border:none;" align="left">2470<xref rid="t1fn3" ref-type="table-fn">c</xref></td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">7</td><td style="border:none;" align="left">42<xref rid="t1fn4" ref-type="table-fn">d</xref></td><td style="border:none;" align="left">2180<xref rid="t1fn3" ref-type="table-fn">c</xref></td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>Binding affinities
(<italic>K</italic><sub>A</sub>) and exchange rates (<italic>k</italic><sub>ex</sub>) for Yb- and Eu-PCTA were determined as described in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Supporting Information</ext-link>.</p></fn><fn id="t1fn2"><label>b</label><p>Determined at 298 K at 9.4 T by
titrating B<sub>1</sub> from 2.34 to 23.4 &#x003bc;T by Zhang et al.,
2017.<sup><xref ref-type="bibr" rid="ref100">100</xref></sup></p></fn><fn id="t1fn3"><label>c</label><p>Determined at 298 K at 9.4 T by
titrating B<sub>1</sub> from 2.35 to 23.5 &#x003bc;T by Zhang et al.,
2017.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup></p></fn><fn id="t1fn4"><label>d</label><p>Determined by fitting CEST titrations
collected using a B<sub>1</sub> of 23.5 &#x003bc;T by Zhang et al.,
2017.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup></p></fn></table-wrap-foot></table-wrap><p>We performed CEST MRI experiments in phantoms containing
one of
the three Ln-PCTA complexes in the absence and presence of lactate
at different concentrations. CEST signals originating from lactate
were readily detected by using a 7T MR scanner for Yb and Eu complexes
(<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>C,D). However,
Pr-PCTA (20 and 40 mM) did not show a significant CEST effect in the
presence of lactate (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>E,F). In the presence of one lactate equivalent, Yb-PCTA produces
a prominent and distinct CEST peak at around 109 ppm, compared to
the typical 0.6&#x02013;0.8 ppm for noncoordinated lactate. Meanwhile,
the shift in the CEST signal induced by Eu-PCTA was slightly smaller
than that previously reported with Eu-DO3A (approximately 14 ppm).
The effect is even more evident when a lower saturation power (8 &#x003bc;T)
is used thanks to a sharper definition of the water peak and reduced
magnetization transfer (MT) effects (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Figure S8</ext-link>). The quantification of the CEST effect, represented by the MT ratio
asymmetry percentage (MTR<sub>asym</sub> %), illustrates a significant
and substantial CEST signal arising from the lactate&#x000b7;Eu-PCTA
and lactate&#x000b7;Yb-PCTA ternary complexes, as illustrated in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>D. This robust CEST
effect observed with the ternary complexes sharply contrasts with
the negligible CEST response observed with Eu&#x02013;Yb&#x02013;PCTA
alone. We hypothesize that the lack of a detectable CEST effect with
Pr-PCTA is likely due to the rapid proton exchange rate (<italic>k</italic><sub>ex</sub>) between the &#x02013;OH group of lactate and bulk water.
For optimal CEST detection, the proton exchange rate should be within
the slow exchange regime, where the frequency difference (&#x00394;&#x003b4;)
between the exchanging sites is greater than the exchange rate (&#x00394;&#x003b4;
&#x0003e; <italic>k</italic><sub>ex</sub>).<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> In
this case, the faster exchange kinetics may shift the system out of
this slow exchange regime, making it difficult to observe a clear
CEST signal. In a previous report, the &#x02013;OH protons of a Pr<sup>3+</sup> complex produced a CEST effect at &#x02212;25.2 ppm with
a <italic>k</italic><sub>ex</sub> of 3.5 &#x000d7; 10<sup>3</sup> s<sup>&#x02013;1</sup>.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> Assuming a similar <italic>k</italic><sub>ex</sub> for lactate-Pr-PCTA, the absence of a clear
CEST peak could be attributed to a chemical shift smaller than the <italic>k</italic><sub>ex</sub>. A small chemical shift is likely due to
a weaker pseudo-contact shift contribution associated with the ligand
field stabilization of this complex. This diminished chemical shift
reduces the separation between the labile proton signal and the bulk
water, further hindering the detection. The <italic>k</italic><sub>ex</sub> for Yb- and Eu-PCTA, calculated using the Omega plot method
at pH 6 and 7,<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> were generally slower
when compared to the values previously reported for DO3A-based SRs.
Interestingly, both SRs exhibited a noteworthy minimum <italic>k</italic><sub>ex</sub> at pH 6, suggesting a similar acid-based proton catalytic
effect (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). The
lower <italic>k</italic><sub>ex</sub> allows the application of relatively
modest saturation powers (B<sub>1</sub> &#x0003c; 12 &#x003bc;T) to detect
the CEST effect. This represents a clear advantage for <italic>in
vivo</italic> translational studies, where lower saturation powers
are generally preferred.</p><p>To better understand the strength of
the interaction, binding affinities
(<italic>K</italic><sub>A</sub>) were determined by acquiring CEST
images of phantom tubes containing 20 mM SRs and titrations of lactate
concentrations between 0 and 600 mM at pH 6&#x02013;7. The amplitude
of the CEST effect was subsequently analyzed using a theoretical binding
model outlined by Zhang et al.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> We assumed
a single binding site for lactate in the model. The analysis enabled
the determination of <italic>K</italic><sub>A</sub> and the maximum
CEST effect at saturation (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A,B). Our findings revealed that all <italic>K</italic><sub>A</sub> values were &#x02264;10<sup>2</sup> M<sup>&#x02013;1</sup>, underscoring a modest interaction between lactate and the SRs (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). These results are
particularly significant for translating SRs into noninvasive <italic>in vivo</italic> metabolic imaging applications in both preclinical
and clinical settings. The determined <italic>K</italic><sub>A</sub> values indicate that lactate remains abundant in the bloodstream
without being depleted by the SRs, confirming the feasibility of using
these complexes for imaging purposes.</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>(A,B) Effect of lactate titration (0&#x02013;0.6
M) on the CEST
effect produced by 20 mM Yb-PCTA (A) or Eu-PCTA (B) at pH 6 and 7.
Lines = fitting line. CEST effect at 109 ppm (Yb-PCTA) and 14 ppm
(Eu-PCTA) were obtained at 298 K after a presaturation of 21 &#x003bc;T,
5 s. (C,D) MTR<sub>asym</sub> % plot of solutions containing 20 mM
Yb-PCTA (C) or Eu-PCTA (D) and 40 mM lactate, citrate or different
combinations of lactate and other metabolites and DMEM, pH 6, 298
K. (E) Omega plot of Eu-PCTA with lactate or lactate and citrate (Lac
+ citrate). (F) CEST images of MC-38 colon adenocarcinoma cell growth
media collected after 48 h of culture with or without 1 mM pyruvate,
mixed with 20 mM Yb-PCTA or Eu-PCTA.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="au4c01020_0003" id="gr3" position="float"/></fig><p>The detection of lactate with the SRs also proved
to be specific
in the presence of potentially confounding &#x02013;OH and &#x02013;NH
resonances present in cell growth media (Dulbecco&#x02019;s modified
Eagle&#x02019;s medium, DMEM). There were no notable differences in
the CEST effect at 109 ppm when lactate-Yb-PCTA was combined with
an equivalent amount of citrate, bicarbonate, or phosphate (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>C). In the case of
Eu-PCTA, neither the addition of these metabolites nor the presence
of DMEM significantly affected the CEST intensity at 10&#x02013;14
ppm. The only exception was citrate, which notably generated a significantly
higher CEST effect (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>D), but no CEST signal was observed for citrate-Eu-PCTA alone.
The exchange rates for lactate-Eu-PCTA and citrate-lactate-Eu-PCTA
were determined to be 3350 and 5610 s<sup>&#x02013;1</sup>, respectively
(pH 7, 21 &#x000b0;C, <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>E). This suggests that the difference in the CEST effect is
not due to the citrate &#x02013;OH CEST effect but rather arises from
a proton catalyzed buffering effect.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> Recently,
it has been reported that lanthanide complexes such as Eu-DO3A can
also be used to detect inorganic phosphate.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> With the PCTA-based complexes, we did not observe any impact in
the presence of 1 equiv of phosphate. While it has been broadly demonstrated
that phosphates interact with lanthanide-based CAs,<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> inorganic phosphate levels vary from 1.1 to 1.2 mM in serum<sup><xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref36">36</xref></sup> and may increase to 1.8&#x02013;2.5 mM in the microenvironment of
some tumors.<sup><xref ref-type="bibr" rid="ref37">37</xref>,<xref ref-type="bibr" rid="ref38">38</xref></sup> Lactate, on the other hand, accumulates
in the TME at usually higher concentrations (2&#x02013;12.9 mM).<sup><xref ref-type="bibr" rid="ref39">39</xref>,<xref ref-type="bibr" rid="ref40">40</xref></sup> Therefore, we do not foresee a significant impact of phosphate on
the detection of extracellular lactate in tumor tissue.</p><p>We also
conducted lactate titrations in serum using both SRs. Results
show a linear correlation between the CEST effect and lactate concentration
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Figure S6C</ext-link>), indicating that the SR offered
a robust and specific tool for measuring lactate in biological solutions.
According to the Human Metabolome Database (hmdb.ca), lactate is present
in blood at concentrations 10<sup>2</sup>&#x02013;10<sup>3</sup> times
higher than those of other metabolites such as pyruvate, acetate,
malate, succinate, and citrate under physiological conditions. Therefore,
we expect the impact of these molecules on the detection of extracellular
lactate with CEST to be negligible. We hypothesize that the apparent
selective interaction between lactate and Ln-PCTA may be facilitated
by its hydroxyl and carboxylate groups, which are less prone to steric
hindrance effects compared to other carboxylic acids like citrate.
Moreover, the &#x02013;OH and &#x02013;CO<sub>2<sup>&#x02013;</sup></sub> groups may effectively coordinate and stabilize the Ln-PCTA complexes.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> The geometry and electronic configuration of
the metal ion within the complex, along with the spatial rearrangement
of the ligands, likely favor the selective binding of lactate over
other monodentate anions (vide structural <sup>1</sup>H NMR study
in <xref rid="fig2" ref-type="fig">Figures <xref rid="fig2" ref-type="fig">2</xref></xref>A and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">S2&#x02013;S5</ext-link>), as previously reported.<sup><xref ref-type="bibr" rid="ref42">42</xref>,<xref ref-type="bibr" rid="ref43">43</xref></sup> Additionally, under pathological conditions such as cancer, the
abundant presence of lactate in the TME likely enhances its preferential
binding to Ln-PCTA.</p><p>To further test the potential of detecting
extracellular lactate,
we added 20 mM of the SRs to samples of MC-38 colon adenocarcinoma
cell growth media collected after 48 h of culture in a normoxic incubator.
Furthermore, we cultured cells with or without pyruvate to test if
the SRs could quantify small changes in lactate excretion. Pyruvate
is the precursor of lactate in the glycolytic pathway and is usually
provided in the growing medium of fast-growing cancer cells. We acquired
CEST images of tubes containing the media, 20 mM lactate, or no lactate
after titrating the pH to 6 in all samples (16 &#x003bc;T, 5 s saturation
pulses as shown in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>F). Lactate concentrations were quantified using calibration
curves based on CEST effects at 14 and 109 ppm. The values calculated
from CEST images ranged between 19.9 and 25.1 mM, which closely aligned
with the results from enzymatic assays (22.8 and 24.6 mM; <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). This strong correlation
demonstrates that SRs and CEST MRI can accurately detect and quantify
metabolic signatures in the TME, offering a reliable tool for profiling
various cancer cell lines.</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>Quantification of
Lactate (mM) Excreted
by MC-38 Cells with CEST MRI and the SRs<xref rid="t2fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center" char="&#x000b1;">Pyr+</th><th style="border:none;" align="center" char="&#x000b1;">Pyr&#x02013;</th></tr></thead><tbody><tr><td style="border:none;" align="left">LDH Kit</td><td style="border:none;" align="char" char="&#x000b1;">24.6&#x000a0;&#x000b1;&#x000a0;3.6</td><td style="border:none;" align="char" char="&#x000b1;">22.8&#x000a0;&#x000b1;&#x000a0;3.1</td></tr><tr><td style="border:none;" align="left">Yb-PCTA CEST</td><td style="border:none;" align="char" char="&#x000b1;">25.1&#x000a0;&#x000b1;&#x000a0;2.3</td><td style="border:none;" align="char" char="&#x000b1;">22.2&#x000a0;&#x000b1;&#x000a0;2.9</td></tr><tr><td style="border:none;" align="left">Eu-PCTA CEST</td><td style="border:none;" align="char" char="&#x000b1;">24.8&#x000a0;&#x000b1;&#x000a0;1.0</td><td style="border:none;" align="char" char="&#x000b1;">19.9&#x000a0;&#x000b1;&#x000a0;0.9</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>Lactate concentrations
(mM) were
determined with an enzymatic LDH kit and CEST MRI with 20 mM Yb- and
Eu-PCTA in samples of MC-38 cells culturing medium. Cells were cultured
for 48 h in the absence (Pyr&#x02212;) or presence of 1 mM pyruvate
(Pyr+). The CEST effect at 14 ppm (Eu-PCTA CEST) or 109 ppm (Yb-PCTA
CEST) was used to calculate the lactate concentration based on a lactate-CEST
calibration line.</p></fn></table-wrap-foot></table-wrap><p>To explore
the feasibility of <italic>in vivo</italic> CEST imaging
of extracellular lactate with the SRs, we tested the cytotoxicity
of the SR <italic>in vitro</italic> and compared it with that of a
Gd-based CA (Magnevist, Bayer) and Eu-DO3A. No significant differences
in cytotoxicity between these complexes were observed, even at the
high concentrations required for CEST imaging (millimolar range) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Figure S9</ext-link>). Furthermore, we incubated Gd-PCTA
with lactate and performed titrations using up to 10 equiv of ZnCl<sub>2</sub> or CaCl<sub>2</sub>, measuring <italic>T</italic><sub>1</sub> values over a 24 h period. The <italic>T</italic><sub>1</sub> values
for the solutions containing ZnCl<sub>2</sub> or CaCl<sub>2</sub> varied
by no more than &#x000b1;1% compared to the samples without zinc/calcium,
indicating that the Ln-PCTA complexes remain stable and unaffected
by transmetalation, even in the presence of highly concentrated cations
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Figure S10</ext-link>). This kinetic stability suggests
that these complexes are suitable for <italic>in vivo</italic> applications.</p><p>Finally, we conducted <italic>in vivo</italic> studies using Yb-PCTA
in healthy and tumor-bearing mice. First, we tested the feasibility
of detection of shiftCEST produced by lactate-Yb-PCTA <italic>in vivo</italic>. We injected 0.2 mmol/kg of a 1:1 mixture of lactate-Yb-PCTA intravenously
into 3 healthy C57BL/6 mice. Then, we acquired CEST images at a fixed
saturation offset (109 ppm) to dynamically monitor the bladder and
muscle tissue over 60 min, as reported previously.<sup><xref ref-type="bibr" rid="ref44">44</xref>,<xref ref-type="bibr" rid="ref45">45</xref></sup> We observed a CEST effect, represented as <italic>M</italic><sub><italic>z</italic></sub> magnetization difference compared to the
baseline (&#x00394;<italic>M</italic><sub><italic>z</italic></sub>/<italic>M</italic><sub>0</sub> %), in the bladder starting from 20 min after
injection, reaching a maximum at 50 min (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>A, D). This effect was not observed when
we injected the same animals with Yb-PCTA dissolved in a 0.9% saline
solution (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>B).
The area under curve of &#x00394;<italic>M</italic><sub><italic>z</italic></sub>/<italic>M</italic><sub>0</sub> % determined in the bladder
over 60 min (AUC<sub>0&#x02013;60min</sub>) was significantly higher
in the animals injected with lactate (<italic>p</italic> = 0.040; <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>C). In the muscle,
no significant difference was observed between the lactate and saline
solution (<italic>p</italic> = 0.879; <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>E). The animal study demonstrated the safe <italic>in vivo</italic> detection of the ternary complex lactate-Yb-PCTA.
Mice received two injections within 48 h and tolerated both well,
indicating no acute toxicity associated with the intravenous administration
of Yb-PCTA at this dose. The dynamics of the CEST effect in the bladder
indicated that the SR was cleared quickly via renal elimination, with
nearly complete clearance at 50 min postinjection (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>C). This is in line with the
typical biodistribution patterns of cyclen- and pyclen-based MR CAs.
Previous reports showed that Ln-PCTA complexes are rapidly excreted,
primarily by the kidneys (and to a lesser extent by the liver), with
nearly complete clearance from the body within 2 h with no Gd<sup>3+</sup> deposition observed in vital organs.<sup><xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref25">25</xref></sup> Based on the moderate affinities of lactate to Yb-PCTA, we hypothesize
that the CEST signal detected in the bladder is in equilibrium between
the initial lactate provided with the injection and the lactate secreted
from the tissues. Nevertheless, we could not determine whether the
lactate-Yb-PCTA ternary complex was excreted intact or if the complex
was reconstituted in the urine&#x02014;an acknowledged limitation.</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p><italic>In vivo</italic> MR imaging of extracellular lactate with
Yb-PCTA in healthy mice. (A) Representative axial anatomical (<italic>T</italic><sub>2</sub>-weighted) and extracellular lactate (CEST
109 ppm) images of healthy C57BL/6 mice before and 60 min after the
intravenous injection of 0.2 mmol/kg SR in saline solution or as a
1:1 mixture of lactate&#x000b7;Yb-PCTA. CEST images were acquired at
a fixed offset (109 ppm) after 3 s presaturation pulses of 14 &#x003bc;T.
(B,D) Quantification of the CEST effect in muscle tissue and bladder
before (pre) and after (post) the injection of 0.2 mmol/kg Yb-PCTA
1:1 lactate&#x000b7;Yb-PCTA (D) or in saline solution (B). (C,E) Area
under curve of the &#x00394;<italic>M</italic><sub><italic>z</italic></sub>/<italic>M</italic><sub>0</sub> % dynamics determined in bladder
(C) and muscle (E). Data expressed as mean &#x000b1; SEM (<italic>n</italic> = 3). *<italic>p</italic> &#x0003c; 0.05; ns, not significant (Student&#x02019;s <italic>t</italic>-test).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="au4c01020_0004" id="gr4" position="float"/></fig><p>In another <italic>in
vivo</italic> experiment,
we applied the
same dynamic CEST MRI protocol to tumor-bearing mice. We inoculated
MC-38 colon adenocarcinoma cells subcutaneously in the lower flank
of C57BL/6 mice. To account for the reduced perfusion of the tumors,
we increased the dose of Yb-PCTA to 1 mmol/kg. We observed CEST contrast
in the tumor region immediately after injection (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>A,C), while no contrast was
detected in the muscle tissue throughout the 60 min scan. The magnitude
of the effect was heterogeneous within the tumors and smaller than
that observed in the bladder, likely due to the uneven distribution
of Yb-PCTA across the tumor and the heterogeneous accumulation of
lactate in the TME. Areas of poor perfusion, such as edematous regions,
showed reduced CEST signals (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>B). These experiments demonstrated that Yb-PCTA CEST
MRI can effectively track extracellular lactate distribution in the
TME. Additionally, they confirmed that Yb-PCTA can be administered
intravenously at high doses with no apparent acute toxicity. Our results
demonstrate the feasibility of detecting lactate using CEST MRI with
Ln-PCTA complexes; nevertheless, the <italic>in vivo</italic> validation
has some limitations due to the small number of animals used in the
preclinical study. To evaluate the full translational potential, further
work should focus on thoroughly understanding the biodistribution
and biosafety of the SRs and evaluating the effectiveness of this
approach in additional disease models. Additionally, while the study
demonstrates a robust CEST signal for lactate with Ln-PCTA complexes <italic>in vitro</italic>, the sensitivity of CEST MRI for detecting extracellular
lactate <italic>in vivo</italic> may be influenced by the tissue vascularity,
perfusion, and motion effects. Ratiometric approaches to quantify
the CEST effect using chiral SRs, or the coinjection of a radiolabeled
and nonradiolabeled Ln-PCTA complex, could be explored to overcome
this limitation. Improving the CEST signal-to-noise ratio with optimized
CEST sequences to reduce motion artifacts will also aid in achieving
quantitative metabolic imaging.<sup><xref ref-type="bibr" rid="ref46">46</xref>,<xref ref-type="bibr" rid="ref47">47</xref></sup></p><fig id="fig5" position="float"><label>Figure 5</label><caption><p><italic>In vivo</italic> MR imaging of extracellular lactate with
Yb-PCTA in MC-38 tumor-bearing mice. (A) Representative axial anatomical
(<italic>T</italic><sub>2</sub>-weighted) and extracellular lactate
(CEST&#x02014;109 ppm) images acquired before (baseline) and 15 min
after a bolus injection of 1.0 mmol/kg of Yb-PCTA. (B) Zoomed view
of an edematous spot within the tumor (black arrows) in the anatomical
(top) and CEST images (bottom). (C) Quantification of the CEST effect
in tumor and muscle tissue before (pre) and after (post) the injection
(<italic>n</italic> = 4; mean &#x000b1; SEM).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="au4c01020_0005" id="gr5" position="float"/></fig></sec><sec id="sec3"><title>Conclusions</title><p>Our study showed that Ln-PCTA complexes
can form ternary complexes
with lactate. High-resolution NMR analysis successfully demonstrated
the interaction between these complexes and lactate. Remarkably, Yb-PCTA
and Eu-PCTA showed only a TSD isomer structure in solution at several
temperatures when coordinated with lactate.<sup><xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref23">23</xref></sup></p><p>We assessed the CEST effect and its specificity for lactate
under
various conditions. Yb-PCTA and Eu-PCTA exhibited strong and unique
CEST signals in the presence of lactate, supporting their potential
as effective CEST SRs. The chemical structure, the typical pathophysiological
concentrations, and cellular localization of other potentially competing
metabolites make them less favored to interact with the SRs. The <italic>K</italic><sub>A</sub> values indicated a moderate binding between
lactate and the SRs, suggesting that physiological lactate levels
remain stable in the bloodstream during the use of these SRs for <italic>in vivo</italic> molecular imaging. Our experiments in cell culture
media and <italic>in vitro</italic> cytotoxicity assessments demonstrated
that these SRs are safe and suited for noninvasive <italic>in vivo</italic> imaging. Furthermore, we validated the safety and efficacy of detection <italic>in vivo</italic>. The preclinical <italic>in vivo</italic> experiments
demonstrated that a 0.2 mmol/kg dose of Yb-PCTA&#x02014;similar to
the clinical dose of Gd-based CAs and much lower than that of typical
iodine CT agents&#x02014;could be detected intact in the mouse bladder,
where most of the injected dose is excreted. Additionally, we detected
extracellular lactate in poorly perfused subcutaneous tumors in mice
using a higher dose. While a robust detection of extracellular lactate
in tumors or organs outside the main excretion routes may require
high SR doses, ongoing optimization of the CEST acquisitions and the <italic>k</italic><sub>ex</sub> and <italic>K</italic><sub>A</sub> of lactate-Ln-PCTA
complexes may help compensate for the moderate CEST SNR generated.
This optimization could potentially enhance the CEST effect, allowing
for lower injection doses and weaker presaturation pulses for CEST
detection. Further thorough analysis of the biosafety will then be
needed for a translation of the results.</p><p>The findings of this
study provide valuable insights for developing
noninvasive metabolic imaging probes in preclinical and clinical settings.
This study demonstrates the potential of combining CEST MRI with safe
inorganic lanthanide-based PCTA complexes to effectively characterize
different cancer cell lines and the metabolic tumor microenvironment.</p></sec><sec id="sec4"><title>Methods</title><sec id="sec4.1"><title>Chemicals and Synthesis</title><p>1.0015 g of pyclen was added
to a 100 mL flask. 5.4043 g of K<sub>2</sub>CO<sub>3</sub> was added
(8.2 equiv). About 34 mL of acetonitrile was added. The slurry was
stirred while cooling. After reaching 5 &#x000b0;C, 2.03 mL of <italic>t</italic>-butyl bromoacetate was added straight and stirred overnight.
The solution was allowed to warm to room temperature and then was
stirred overnight. The solution was filtered to remove the salts and
then split into two separate vessels. An equivolume of water was added
to each. 1.8 mL of 1 M HCl was added to lower the pH from 11.3 to
3&#x02013;4. An equivalent of 0.5 M EuCl<sub>3</sub>, YbCl<sub>3</sub>, or PrCl<sub>3</sub> was added. The Eu and Yb solutions were heated
to 45&#x02013;55 &#x000b0;C for complexation. The Pr solutions were heated
to 75 &#x000b0;C for complexation. Throughout the day to form the complex,
1 M NaOH was used to maintain pH = 4&#x02013;6 (Eu<sup>3+</sup>), pH
= 5.3&#x02013;5.6 (Yb<sup>3+</sup>), and pH = 5.8&#x02013;6.5 (Pr<sup>3+</sup>). Acetonitrile was replenished as needed to maintain a consistent
volume. The complexation was monitored by HPLC. After complexation,
the metal acts as a catalyst to remove the <italic>t</italic>-butyl
esters. The reactions were stopped after &#x0003e;80% completion. The solutions
were used as a stock solution for preparative HPLC purification. A
Phenomenex Luna C18(2) column connected to a Waters DeltaPrep system
was used. A simple gradient using 0.025% TFA in CH<sub>3</sub>CN/H<sub>2</sub>O modifiers was used. Collected fractions were freeze-dried
to obtain the purified complexes. Final purities were &#x02265;98%
by HPLC. Identities were verified by mass spectrometry. The solids
were analyzed by ICP&#x02013;MS to quantify the metal content: 21.8%
Eu in Eu-PCTA, 24.9% Yb in Yb-PCTA, and 17.4% Pr in Pr-PCTA. Based
on the percent metal values, it is likely the compounds were isolated
as a 1TFA salt with a small percentage of residual water. Isolation
of a 1TFA salt was observed in our laboratory with similar complexes.
Percent yields are based on the formula weight of the 1TFA salt. Synthetic
quantities, molar equivalents, and chemical yields are shown in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Table S1</ext-link> from the Supporting Information. Chemical
structures and IUPAC names were obtained using Chemaxon MarvinSketch
24.1.2.<sup><xref ref-type="bibr" rid="ref48">48</xref></sup></p></sec><sec id="sec4.2"><title>Permeability Artificial
Membrane Penetration Assay</title><p>The PAMPA was performed as previously
described.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> An artificial membrane was
produced in a donor plate (MAIPNTR10
PDVD, Merck) by adding lecithin (<sc>l</sc>-&#x003b1;-phosphatidylcholin,
lecithin, Merck) in dodecane (Merck) solution (1% w/v). To assess
the membrane permeability of the compounds, 200 &#x003bc;L of 1 mM Ln-PCTA
complexes in PBS was pipetted into each donor well of the PAMPA plate.
The wells of the acceptor plate (96-deepwell plate, Thermo Scientific)
were each filled with 1100 &#x003bc;L PBS. The donor plate was placed
into the acceptor and then the plates were left at room temperature
for 21 h, after which the contents of the acceptor wells were analyzed
by HPLC and quantified using a calibration curve. Propranolol was
used as a positive control. The assay was performed in triplicate
(Eu-PCTA and propranolol: duplicate).</p></sec><sec id="sec4.3"><title>NMR Experiments</title><p>NMR measurement of the BMS of cell
growing medium containing Yb-PCTA or Gd-DOTA was performed by measuring
the chemical shift of <italic>t</italic>Bu as previously described.<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> PyMT-derived ML1B1B1 breast cancer cells were
cultured as described in &#x0201c;<xref rid="sec4.12" ref-type="other">Cell Culture</xref>&#x0201d;. For experiments, cells were seeded at a density of 5 &#x000d7;
10<sup>3</sup>/well in 96-well plates. After 24 h, at 90% confluence,
growing medium was removed, and cells were incubated with DMEM containing
2 mM Yb-PCTA or Gd-DOTA (Dotarem, Guerbet) for 2 h. Wells containing
no cells were processed in the same way and were used as negative
control. After 2 h, the growing medium was collected, centrifuged
at 10 g for 5 min, and stored at 4 &#x000b0;C until further analysis.
For the BMS NMR measurements, samples of the growing medium were mixed
with 10% <italic>t</italic>Bu and transferred to 5 mm NMR tubes. The
concentration of Yb-PCTA and Gd-DOTA was derived from the chemical
shift of <italic>t</italic>Bu &#x02013;OH peak as previously described.<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> The concentration of the lanthanide complexes
was derived by the chemical shift of <italic>t</italic>Bu and compared
with that of wells without cells.</p><p>NMR solutions to analyze the
interaction between lactate and SRs were prepared using deuterated
solvent D<sub>2</sub>O. The <sup>1</sup>H NMR spectra were acquired
on a Bruker AVANCE III 400 spectrometer (Bruker, Massachusetts, USA)
operating at a frequency of 400.13 MHz (<sup>1</sup>H), at various
temperatures, using a 5 mm z-gradient inverse probe (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Figures S4&#x02013;S6</ext-link>). 2D COSY and EXSY spectra were acquired
on a Bruker AVANCE NEO 600 spectrometer, using BBFO 5 mm iProbe (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Figure S7</ext-link>). Subsequently, the resulting data
were processed and analyzed using Topspin v4.0 (Bruker) and MestReNova
9.1 (Mestrelab).</p></sec><sec id="sec4.4"><title>CEST MRI Experiments</title><p>Phantoms were
acquired by using
a 7 T (300 MHz) preclinical MRI scanner (Bruker BioSpec 70/30, Bruker
BioSpin, Ettlingen, Germany) using an 86 mm diameter <sup>1</sup>H
transceiver volume coil (Bruker). 2D CEST coronal images were acquired
using a previously reported FISP sequence with the following parameters:<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> echo time (TE) 1.80 ms, repetition time (TR)
3.60 ms, flip angle 30&#x000b0;, field of view (FOV) 100 &#x000d7; 80 mm,
slice thickness 1 mm, matrix size 128 &#x000d7; 80, resolution 0.78 &#x000d7;
0.75 &#x000d7; 1 mm. CEST presaturation consisted of 5 s, continuous
rectangular pulses with a B<sub>1</sub> ranging between 2 and 21 &#x003bc;T
depending on the experiment. Different sets of saturation offsets
were used depending on the Ln-PCTA. Phantoms consisting of 0.3 mL
Eppendorf tubes were placed in a customized 3D-printed phantom holder,
filled with 2% agarose in order to reduce B<sub>0</sub>, B<sub>1</sub>, and temperature fluctuations.</p></sec><sec id="sec4.5"><title>CEST Spectra</title><p>Z-spectra
were acquired in phantom tubes
containing 50 mM of Yb- and Eu-PCTA (Pr-PCTA: 40 mM) mixed with 50
mM lactate (for Pr-PCTA: 40 mM) in 50 mM HEPES buffer at pH 6 and
7, 298 K. Tubes without lactate with Ln-PCTA at the same concentrations,
pH, and buffer concentration were used as controls. 5 s presaturation
pulses were used with different B<sub>1</sub> values depending on
the experiment. Raw spectra were fitted to Lorentzian line shapes
based on a two-pool model (water, lactate&#x000b7;Ln-PCTA) using an in-house-written
MATLAB script. CEST effect with respect to saturation offset (&#x00394;&#x003c9;)
was quantified as MT ratio asymmetry percentage (MTR<sub>asym</sub> %), as per MTR<sub>asym</sub> % = [(<italic>M</italic><sub><italic>z</italic></sub><sup>&#x02013;&#x00394;&#x003c9;</sup> &#x02013; <italic>M</italic><sub><italic>z</italic></sub><sup>+&#x00394;&#x003c9;</sup>)/<italic>M</italic><sub>0</sub>] &#x000d7; 100, unless differently
specified.</p></sec><sec id="sec4.6"><title>Calibration Curves for Lactate Determination
with CEST MRI</title><p>Phantoms containing 20 mM SRs mixed with 0&#x02013;40
mM lactate
in 50 mM HEPES buffer or human serum (Sigma-Aldrich) at pH 6 and 7,
298 K were used to generate calibration curves between the amplitude
of CEST effect at 14 ppm (Eu-PCTA) or 109 ppm (Yb-PCTA) and lactate
concentration (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Figure S6</ext-link>). CEST presaturation
consisted of 5 s, 16 &#x003bc;T continuous pulses. Z-spectra were fitted
to Lorentzian line shapes (two pools: water and lactate&#x000b7;Ln-PCTA).
CEST images were acquired in triplicate.</p></sec><sec id="sec4.7"><title>Exchange Rates Determination</title><p>Exchange rates were determined
using the Omega plot method.<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> 20 mM, 1:1
solution of lactate, and SRs at pH 6 or 7 were scanned as described
before using CEST presaturation pulses with B<sub>1</sub> ranging
between 2 and 20 &#x003bc;T.</p></sec><sec id="sec4.8"><title>Binding Affinity Determination</title><p>Binding
affinity for
the SRs&#x02013;lactate complexes was determined using the CEST<sub>%</sub> effect at 14 ppm (Eu-PCTA) or 109 ppm (Yb-PCTA) at pH 6 and
7, 298 K. CEST<sub>%</sub> was determined as per CEST % = [1 &#x02013;
(<italic>M</italic><sub><italic>z</italic></sub><sup>&#x00394;&#x003c9;</sup>/<italic>M</italic><sub>0</sub>)] &#x000d7; 100, using 20 mM SRs and
lactate concentrations ranging between 0 and 600 mM. After background
correction, CEST<sub>%</sub> for each lactate concentration was fitted
according to a previously reported equation to determine <italic>K</italic><sub>A</sub>.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup></p></sec><sec id="sec4.9"><title>Competition Experiment</title><p>Selectivity of the CEST effect
for lactate was tested in phantoms containing 20 mM SRs and different
combinations of 40 mM lactate, citrate, NaHCO<sub>3</sub>, NaH<sub>2</sub>PO<sub>4</sub>, and DMEM at pH 7, 298 K. CEST images were
acquired as described above with 5 s presaturation pulses with a B<sub>1</sub> of 16 &#x003bc;T. Exchange rates were determined with the Omega
plot as described in &#x0201c;<xref rid="sec4.7" ref-type="other">Exchange rates determination</xref>&#x0201d;.</p></sec><sec id="sec4.10"><title>Relaxometry Experiments</title><p>To determine <italic>r</italic><sub>1</sub> relaxivity, 0.1&#x02013;1 mM Eu-PCTA phantoms
and 0&#x02013;10
mM Yb-PCTA, dissolved in human serum, were prepared in 0.3 mL tubes. <italic>T</italic><sub>1</sub> maps were acquired by using a standard 2D
RARE VTR sequence with 15 TRs. Experiments were performed at 310 K
in human serum. <italic>T</italic><sub>1</sub> maps were generated
by using the MRI Analysis Calculator for ImageJ (Fiji).</p></sec><sec id="sec4.11"><title>Stability
in the Presence of ZnCl<sub>2</sub> and CaCl<sub>2</sub></title><p>The effect of physiological cations on the detection of
lactate was tested using Gd-PCTA as a surrogate for Yb- and Eu-PCTA.
Phantoms containing 0.5 mM Gd-PCTA, 0.5 mM Gd-PCTA with 10 mM lactate,
0.5 mM Gd-PCTA, 10 mM lactate, and different amounts of ZnCl<sub>2</sub> or CaCl<sub>2</sub> (from 0.5 to 5 mM, corresponding to 1&#x02013;10
equiv) were scanned at 7 T, 298 K to acquire <italic>T</italic><sub>1</sub> maps over 24 h. pH was titrated to 7. <italic>T</italic><sub>1</sub> maps were acquired and analyzed as described in &#x0201c;<xref rid="sec4.10" ref-type="other">Relaxometry Experiments</xref>&#x0201d;. <italic>T</italic><sub>1</sub> values were plotted against the ZnCl<sub>2</sub>/CaCl<sub>2</sub> concentration (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Figure S10A,C</ext-link>).
To monitor the trend of <italic>T</italic><sub>1</sub> values over
time, <italic>T</italic><sub>1</sub> values were normalized to the
first acquired <italic>T</italic><sub>1</sub> map, as per <italic>T</italic><sub>1</sub> change % = (<italic>T</italic><sub>1(<italic>t</italic>)</sub>/<italic>T</italic><sub>1(<italic>t</italic>=0)</sub>) &#x000d7; 100, and then divided by the <italic>T</italic><sub>1</sub> change % of the tube containing no ZnCl<sub>2</sub>/CaCl<sub>2</sub> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Figure S10B,D</ext-link>).</p></sec><sec id="sec4.12"><title>Cell Culture</title><p>PyMT-derived
ML1B1B1 cells (donated by
Dr. Sabrina Hoffmann) were cultured with DMEM supplemented with 10%
FCS, 1% penicillin/streptomycin, <sc>l</sc>-glutamine, 1 mM sodium
pyruvate, 1% MEM amino acids, and 10 mM. MC-38 cells (Kerafast) were
cultured with DMEM supplemented with 10% FCS, 1% penicillin/streptomycin, <sc>l</sc>-glutamine, 1 mM sodium pyruvate, and 15 mM HEPES buffer. Cells
were regularly tested for mycoplasma contaminations. For experiments,
cells were trypsinized and counted with trypan blue and then processed
differently according to the experiment.</p></sec><sec id="sec4.13"><title>Cell Culture Experiment
to Detect Lactate Excreted by Cancer
Cells</title><p>MC-38 cells were cultured as described in &#x0201c;<xref rid="sec4.12" ref-type="other">Cell Culture</xref>&#x0201d;. For experiments, cells
were seeded at a density of 5 &#x000d7; 10<sup>5</sup>/well in 6-well
plates in DMEM supplemented with or without 1 mM sodium pyruvate.
After 48 h, the growing medium was collected and centrifuged for 30
min at 4 &#x000b0;C in 10 kDa filter tubes. For CEST measurements of
lactate excreted by the cancer cells, the filtered growing media were
transferred to 0.3 mL tubes, Yb- or Eu-PCTA was added to a final concentration
of 20 mM, and pH was adjusted to 7.0; then, CEST images were acquired
as described before using presaturation pulses of 5 s with a B<sub>1</sub> of 16 &#x003bc;T. Lactate-CEST (1 &#x02013; <italic>M</italic><sub><italic>z</italic></sub>/<italic>M</italic><sub>0</sub> %) calibration
lines were used to quantify the lactate concentration. An enzymatic
LDH kit (Lactate Assay Kit II, Sigma-Aldrich) was used to cross-validate
the lactate concentration. Lactate concentrations determined via the
enzymatic kit and the CEST images are reported in <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>.</p></sec><sec id="sec4.14"><title>Cytotoxicity</title><p>Cytotoxicity
of Yb-, Eu-, and Pr-PCTA
complexes was evaluated using an MTS assay (Promega, Madison, WI,
USA) and compared with the previously reported SR (Eu-DO3A) and Gd-DTPA
(Magnevist, Bayer). MC-38 cells were cultured as described in &#x0201c;<xref rid="sec4.12" ref-type="other">Cell Culture</xref>&#x0201d;. For experiments, cells
were seeded at a density of 2 &#x000d7; 10<sup>3</sup> cells/well in
96-well plates in triplicate. After 24 h, cells were incubated for
2 h with 5 mM Yb-, Eu-, Pr-PCTA, 5 mM Eu-DO3A, or 10 &#x003bc;M Magnevist
dissolved in phenol red-free DMEM, and then the MTS reagent mix was
added. After further incubation at 37 &#x000b0;C for 2 or 4 h, the absorbance
at 490 nm was measured. Cytotoxicity was determined as viability versus
control by comparing the absorbance of treated cells to control cells,
expressed as % (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Figure S9</ext-link>).</p></sec><sec id="sec4.15"><title>Animal Experiments</title><p>Animal experiments with C57Bl/6
mice were conducted following German federal regulations on the use
and care of experimental animals and approved by the local authorities
(Regierungspr&#x000e4;sidium T&#x000fc;bingen). A total of 7 (3 healthy
and 4 tumor-bearing) female mice were used. Four mice were injected
subcutaneously in the lower flank with 5 &#x000d7; 10<sup>5</sup> MC-38
cells, and tumors were allowed to grow for 2 weeks. For the imaging
experiments, mice were kept under anesthesia using isoflurane in pure
oxygen (5% induction, 1.5% maintenance), and a catheter was placed
in a tail vein.</p></sec><sec id="sec4.16"><title><italic>In Vivo</italic> Dynamic CEST MRI</title><p>Axial 2D
CEST images were acquired with the same FISP sequence used for phantoms,
with a spatial resolution of 0.6 &#x000d7; 0.6 &#x000d7; 1 mm. For the experiment
with healthy mice, 20 preinjection CEST images were acquired at 109
ppm after a presaturation of 3 s, 14 &#x003bc;T continuous pulses to
determine the baseline, and then further CEST images were acquired
every 5 min for the first 30 min and at 40, 50, and 60 min after a
bolus i.v. injection of 0.2 mmol/kg of Yb-PCTA dissolved in 0.9% saline
solution. After 48 h, the experiment was repeated by injecting a 1:1
mixture of 0.2 mmol/kg lactate*Yb-PCTA. Twenty CEST images were acquired
at each time point and averaged. The same imaging protocol was applied
to MC-38 tumor-bearing mice. Tumor-bearing mice were injected with
1 mmol/kg of Yb-PCTA dissolved in 0.9% saline solution.</p><p>The
dynamics of the CEST effect were determined for bladder and muscle
tissue (healthy mice) and in tumor and muscle (tumor bearing mice),
as &#x00394;<italic>M</italic><sub><italic>z</italic></sub>/<italic>M</italic><sub>0</sub> % = [1 + (<italic>M</italic><sub><italic>z</italic></sub><sup>&#x00394;&#x003c9;</sup><sub>(<italic>t</italic>=0)</sub>/<italic>M</italic><sub>0</sub><sup>&#x00394;&#x003c9;</sup><sub>(<italic>t</italic>=0)</sub>) &#x02013; (<italic>M</italic><sub><italic>z</italic></sub><sup>&#x00394;&#x003c9;</sup><sub>(<italic>t</italic>)</sub>/<italic>M</italic><sub>0</sub><sup>&#x00394;&#x003c9;</sup><sub>(<italic>t</italic>)</sub>)] &#x000d7; 100. Area under curve of the CEST effect dynamics
over 60 min (AUC<sub>0&#x02013;60&#x000a0;min</sub>) was calculated with
GraphPad PRISM 10.1.1 (GraphPad Software, Boston, MA USA). AUC<sub>0&#x02013;60min</sub> of bladder and muscle after injection of saline
or lactate was compared with a two-tailed Student&#x02019;s <italic>t</italic>-test, using GraphPad. A statistically significant difference
was assumed for <italic>p</italic> &#x0003c; 0.05.</p><p>Anatomical <italic>T</italic><sub>1</sub>-and <italic>T</italic><sub>2</sub>-weighted
images were acquired for coregistration of
the CEST images (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">Supporting Information</ext-link>).</p></sec></sec></body><back><notes id="notes1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information
is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/jacsau.4c01020?goto=supporting-info">https://pubs.acs.org/doi/10.1021/jacsau.4c01020</ext-link>.<list id="silist" list-type="simple"><list-item><p>Additional detailed descriptions
of all the experimental
procedures and materials, complex synthesis, MRI sequences, PAMPA,
BMS NMR, relaxometry and cytotoxicity results, and additional relevant <sup>1</sup>H NMR and CEST spectra (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/jacsau.4c01020/suppl_file/au4c01020_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="au4c01020_si_001.pdf"><caption><p>au4c01020_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes3"><title>Author Contributions</title><p>The manuscript
was written with contributions from all authors. All authors have
approved the final version of the manuscript. CRediT: <bold>Remy Chiaffarelli</bold> conceptualization, data curation, formal analysis, investigation,
visualization, writing - original draft, writing - review &#x00026; editing; <bold>Pedro Fernandes Cruz</bold> investigation, methodology, validation,
visualization, writing - review &#x00026; editing; <bold>Jonathan Cotton</bold> investigation, methodology, validation; <bold>Tjark Kelm</bold> formal
analysis, investigation, software, validation, visualization; <bold>Slade Lee</bold> investigation, methodology; <bold>Mohammad Ghaderian</bold> validation; <bold>Max Zimmermann</bold> data curation, investigation,
methodology, software; <bold>Carlos F.G.C. Geraldes</bold> funding
acquisition, investigation, supervision, writing - original draft,
writing - review &#x00026; editing; <bold>Paul Jurek</bold> investigation,
methodology, writing - original draft, writing - review &#x00026; editing; <bold>Andre F Martins</bold> conceptualization, funding acquisition, investigation,
methodology, project administration, resources, supervision, visualization,
writing - original draft, writing - review &#x00026; editing.</p></notes><notes notes-type="COI-statement" id="notes2"><p>The authors
declare no competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>A.F.M. acknowledges
the support from the Deutsche
Forschungsgemeinschaft (DFG, German Research Foundation)&#x02014;516238665
and 527345502. This work was supported by the Cluster of Excellence
iFIT (EXC 2180) &#x0201c;Image-Guided and Functionally Instructed Tumor
Therapies&#x0201d;, University of Tuebingen, Germany, the Werner Siemens
Foundation, the Alexander von Humboldt Foundation within the framework
of the Sofja Kovalevskaja Award (to AFM), and the DKTK German Cancer
Consortium Innovation program &#x0201c;HYPERBOLIC. C.F.G.C.G. and P.F.C.
acknowledge the Foundation for Science and Technology (FCT), Portugal,
for funding the CQC-IMS (UID/QUI/00313/2020, UIDP/00313/2020, and
POCI-01-0145-FEDER-027996) of the University of Coimbra.</p></ack><glossary id="dl1"><def-list><title>Abbreviations</title><def-item><term>AUC</term><def><p>area
under curve</p></def></def-item><def-item><term>BMS</term><def><p>bulk magnetic susceptibility</p></def></def-item><def-item><term>CEST</term><def><p>chemical exchange saturation
transfer</p></def></def-item><def-item><term>DMEM</term><def><p>Dulbecco&#x02019;s
Modified Eagle Medium</p></def></def-item><def-item><term>DOTA</term><def><p>1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid</p></def></def-item><def-item><term>DO3A</term><def><p>1,4,7,10-tetraazacyclododecane-1,4,7-triacetic
acid</p></def></def-item><def-item><term>MRI</term><def><p>magnetic
resonance imaging</p></def></def-item><def-item><term>MTR<sub>asym</sub> %</term><def><p>Magnetization transfer ratio asymmetry percentage</p></def></def-item><def-item><term>NMR</term><def><p>Nuclear magnetic
resonance</p></def></def-item><def-item><term>PAMPA</term><def><p>permeability artificial membrane penetration assay</p></def></def-item><def-item><term>SAP</term><def><p>square antiprism</p></def></def-item><def-item><term>SR</term><def><p>shift reagent</p></def></def-item><def-item><term>PCTA</term><def><p>3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetic
acid</p></def></def-item><def-item><term>TSAP</term><def><p>twisted
square antiprism</p></def></def-item><def-item><term>TSD</term><def><p>twisted snub disphenoid.</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>P&#x000e9;rez-Tom&#x000e1;s</surname><given-names>R.</given-names></name>; <name><surname>P&#x000e9;rez-Guill&#x000e9;n</surname><given-names>I.</given-names></name>
<article-title>Lactate in the Tumor Microenvironment:
An Essential Molecule in Cancer Progression and Treatment</article-title>. <source>Cancers</source>
<year>2020</year>, <volume>12</volume> (<issue>11</issue>), <fpage>3244</fpage><pub-id pub-id-type="doi">10.3390/cancers12113244</pub-id>.<pub-id pub-id-type="pmid">33153193</pub-id>
</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Golman</surname><given-names>K.</given-names></name>; <name><surname>in &#x02019;t Zandt</surname><given-names>R.</given-names></name>; <name><surname>Thaning</surname><given-names>M.</given-names></name>
<article-title>Real-Time Metabolic Imaging</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<year>2006</year>, <volume>103</volume> (<issue>30</issue>), <fpage>11270</fpage>&#x02013;<lpage>11275</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0601319103</pub-id>.<pub-id pub-id-type="pmid">16837573</pub-id>
</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Gallagher</surname><given-names>F. A.</given-names></name>; <name><surname>Kettunen</surname><given-names>M. I.</given-names></name>; <name><surname>Hu</surname><given-names>D.-E.</given-names></name>; <name><surname>Jensen</surname><given-names>P. R.</given-names></name>; <name><surname>Zandt</surname><given-names>R. I. &#x02019;t.</given-names></name>; <name><surname>Karlsson</surname><given-names>M.</given-names></name>; <name><surname>Gisselsson</surname><given-names>A.</given-names></name>; <name><surname>Nelson</surname><given-names>S. K.</given-names></name>; <name><surname>Witney</surname><given-names>T. H.</given-names></name>; <name><surname>Bohndiek</surname><given-names>S. E.</given-names></name>; <name><surname>Hansson</surname><given-names>G.</given-names></name>; <name><surname>Peitersen</surname><given-names>T.</given-names></name>; <name><surname>Lerche</surname><given-names>M. H.</given-names></name>; <name><surname>Brindle</surname><given-names>K. M.</given-names></name>
<article-title>Production of Hyperpolarized [1,4&#x02013;13C2]Malate
from [1,4&#x02013;13C2]Fumarate Is a Marker of Cell Necrosis and Treatment
Response in Tumors</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<year>2009</year>, <volume>106</volume> (<issue>47</issue>), <fpage>19801</fpage>&#x02013;<lpage>19806</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0911447106</pub-id>.<pub-id pub-id-type="pmid">19903889</pub-id>
</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>De
Feyter</surname><given-names>H. M.</given-names></name>; <name><surname>Behar</surname><given-names>K. L.</given-names></name>; <name><surname>Corbin</surname><given-names>Z. A.</given-names></name>; <name><surname>Fulbright</surname><given-names>R. K.</given-names></name>; <name><surname>Brown</surname><given-names>P. B.</given-names></name>; <name><surname>McIntyre</surname><given-names>S.</given-names></name>; <name><surname>Nixon</surname><given-names>T. W.</given-names></name>; <name><surname>Rothman</surname><given-names>D. L.</given-names></name>; <name><surname>de Graaf</surname><given-names>R. A.</given-names></name>
<article-title>Deuterium Metabolic Imaging (DMI) for MRI-Based 3D
Mapping of Metabolism in Vivo</article-title>. <source>Sci. Adv.</source>
<year>2018</year>, <volume>4</volume> (<issue>8</issue>), <elocation-id>eaat7314</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aat7314</pub-id>.<pub-id pub-id-type="pmid">30140744</pub-id>
</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>DeBrosse</surname><given-names>C.</given-names></name>; <name><surname>Nanga</surname><given-names>R. P. R.</given-names></name>; <name><surname>Bagga</surname><given-names>P.</given-names></name>; <name><surname>Nath</surname><given-names>K.</given-names></name>; <name><surname>Haris</surname><given-names>M.</given-names></name>; <name><surname>Marincola</surname><given-names>F.</given-names></name>; <name><surname>Schnall</surname><given-names>M. D.</given-names></name>; <name><surname>Hariharan</surname><given-names>H.</given-names></name>; <name><surname>Reddy</surname><given-names>R.</given-names></name>
<article-title>Lactate Chemical Exchange Saturation Transfer (LATEST) Imaging in
Vivo: A Biomarker for LDH Activity</article-title>. <source>Sci. Rep.</source>
<year>2016</year>, <volume>6</volume> (<issue>1</issue>), <fpage>19517</fpage><pub-id pub-id-type="doi">10.1038/srep19517</pub-id>.<pub-id pub-id-type="pmid">26794265</pub-id>
</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Radke</surname><given-names>K. L.</given-names></name>; <name><surname>Abrar</surname><given-names>D. B.</given-names></name>; <name><surname>Frenken</surname><given-names>M.</given-names></name>; <name><surname>Wilms</surname><given-names>L. M.</given-names></name>; <name><surname>Kamp</surname><given-names>B.</given-names></name>; <name><surname>Boschheidgen</surname><given-names>M.</given-names></name>; <name><surname>Liebig</surname><given-names>P.</given-names></name>; <name><surname>Ljimani</surname><given-names>A.</given-names></name>; <name><surname>Filler</surname><given-names>T. J.</given-names></name>; <name><surname>Antoch</surname><given-names>G.</given-names></name>; <name><surname>Nebelung</surname><given-names>S.</given-names></name>; <name><surname>Wittsack</surname><given-names>H.-J.</given-names></name>; <name><surname>M&#x000fc;ller-Lutz</surname><given-names>A.</given-names></name>
<article-title>Chemical Exchange
Saturation Transfer for Lactate-Weighted Imaging at 3 T MRI: Comprehensive
In Silico, In Vitro, In Situ, and In Vivo Evaluations</article-title>. <source>Tomography</source>
<year>2022</year>, <volume>8</volume> (<issue>3</issue>), <fpage>1277</fpage>&#x02013;<lpage>1292</lpage>. <pub-id pub-id-type="doi">10.3390/tomography8030106</pub-id>.<pub-id pub-id-type="pmid">35645392</pub-id>
</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Aime</surname><given-names>S.</given-names></name>; <name><surname>Delli Castelli</surname><given-names>D.</given-names></name>; <name><surname>Fedeli</surname><given-names>F.</given-names></name>; <name><surname>Terreno</surname><given-names>E.</given-names></name>
<article-title>A Paramagnetic
MRI-CEST
Agent Responsive to Lactate Concentration</article-title>. <source>J.
Am. Chem. Soc.</source>
<year>2002</year>, <volume>124</volume> (<issue>32</issue>), <fpage>9364</fpage>&#x02013;<lpage>9365</lpage>. <pub-id pub-id-type="doi">10.1021/ja0264044</pub-id>.<pub-id pub-id-type="pmid">12167018</pub-id>
</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Martins</surname><given-names>A. F.</given-names></name>; <name><surname>Mai</surname><given-names>Y.</given-names></name>; <name><surname>Zhao</surname><given-names>P.</given-names></name>; <name><surname>Funk</surname><given-names>A. M.</given-names></name>; <name><surname>Clavijo Jordan</surname><given-names>M. V.</given-names></name>; <name><surname>Zhang</surname><given-names>S.</given-names></name>; <name><surname>Chen</surname><given-names>W.</given-names></name>; <name><surname>Wu</surname><given-names>Y.</given-names></name>; <name><surname>Sherry</surname><given-names>A. D.</given-names></name>
<article-title>Imaging Extracellular Lactate In Vitro and In Vivo
Using CEST MRI and a Paramagnetic Shift Reagent</article-title>. <source>Chem. Weinh. Bergstr. Ger.</source>
<year>2017</year>, <volume>23</volume> (<issue>8</issue>), <fpage>1752</fpage>&#x02013;<lpage>1756</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201604558</pub-id>.</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Kartamihardja</surname><given-names>A. A. P.</given-names></name>; <name><surname>Nakajima</surname><given-names>T.</given-names></name>; <name><surname>Kameo</surname><given-names>S.</given-names></name>; <name><surname>Koyama</surname><given-names>H.</given-names></name>; <name><surname>Tsushima</surname><given-names>Y.</given-names></name>
<article-title>Impact of
Impaired Renal Function on Gadolinium Retention After Administration
of Gadolinium-Based Contrast Agents in a Mouse Model</article-title>. <source>Invest. Radiol.</source>
<year>2016</year>, <volume>51</volume> (<issue>10</issue>), <fpage>655</fpage>&#x02013;<lpage>660</lpage>. <pub-id pub-id-type="doi">10.1097/RLI.0000000000000295</pub-id>.<pub-id pub-id-type="pmid">27299580</pub-id>
</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Tircs&#x000f3;</surname><given-names>G.</given-names></name>; <name><surname>Kovacs</surname><given-names>Z.</given-names></name>; <name><surname>Sherry</surname><given-names>A. D.</given-names></name>
<article-title>Equilibrium and
Formation/Dissociation
Kinetics of Some Ln(III)PCTA Complexes</article-title>. <source>Inorg.
Chem.</source>
<year>2006</year>, <volume>45</volume> (<issue>23</issue>), <fpage>9269</fpage>&#x02013;<lpage>9280</lpage>. <pub-id pub-id-type="doi">10.1021/ic0608750</pub-id>.<pub-id pub-id-type="pmid">17083226</pub-id>
</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Port</surname><given-names>M.</given-names></name>; <name><surname>Raynal</surname><given-names>I.</given-names></name>; <name><surname>Vander Elst</surname><given-names>L.</given-names></name>; <name><surname>Muller</surname><given-names>R. N.</given-names></name>; <name><surname>Dioury</surname><given-names>F.</given-names></name>; <name><surname>Ferroud</surname><given-names>C.</given-names></name>; <name><surname>Guy</surname><given-names>A.</given-names></name>
<article-title>Impact of
Rigidification on Relaxometric
Properties of a Tricyclic Tetraazatriacetic Gadolinium Chelate</article-title>. <source>Contrast Media Mol. Imaging</source>
<year>2006</year>, <volume>1</volume> (<issue>3</issue>), <fpage>121</fpage>&#x02013;<lpage>127</lpage>. <pub-id pub-id-type="doi">10.1002/cmmi.99</pub-id>.<pub-id pub-id-type="pmid">17193688</pub-id>
</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Aime</surname><given-names>S.</given-names></name>; <name><surname>Botta</surname><given-names>M.</given-names></name>; <name><surname>Geninatti Crich</surname><given-names>S.</given-names></name>; <name><surname>Giovenzana</surname><given-names>G. B.</given-names></name>; <name><surname>Jommi</surname><given-names>G.</given-names></name>; <name><surname>Pagliarin</surname><given-names>R.</given-names></name>; <name><surname>Sisti</surname><given-names>M.</given-names></name>
<article-title>Synthesis and NMR Studies
of Three Pyridine-Containing Triaza Macrocyclic Triacetate Ligands
and Their Complexes with Lanthanide Ions</article-title>. <source>Inorg.
Chem.</source>
<year>1997</year>, <volume>36</volume> (<issue>14</issue>), <fpage>2992</fpage>&#x02013;<lpage>3000</lpage>. <pub-id pub-id-type="doi">10.1021/ic960794b</pub-id>.<pub-id pub-id-type="pmid">11669949</pub-id>
</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Aime</surname><given-names>S.</given-names></name>; <name><surname>Botta</surname><given-names>M.</given-names></name>; <name><surname>Crich</surname><given-names>S. G.</given-names></name>; <name><surname>Giovenzana</surname><given-names>G. B.</given-names></name>; <name><surname>Jommi</surname><given-names>G.</given-names></name>; <name><surname>Pagliarin</surname><given-names>R.</given-names></name>; <name><surname>Sisti</surname><given-names>M.</given-names></name>
<article-title>MRI Contrast Agents:
Macrocyclic Lanthanide(III) Complexes with Improved Relaxation Efficiency</article-title>. <source>J. Chem. Soc. Chem. Commun.</source>
<year>1995</year>, <volume>18</volume>, <fpage>1885</fpage>&#x02013;<lpage>1886</lpage>. <pub-id pub-id-type="doi">10.1039/c39950001885</pub-id>.</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Kim</surname><given-names>W. D.</given-names></name>; <name><surname>Kiefer</surname><given-names>G. E.</given-names></name>; <name><surname>Maton</surname><given-names>F.</given-names></name>; <name><surname>McMillan</surname><given-names>K.</given-names></name>; <name><surname>Muller</surname><given-names>R. N.</given-names></name>; <name><surname>Sherry</surname><given-names>A. D.</given-names></name>
<article-title>Relaxometry, Luminescence Measurement, Electrophoresis,
and Animal Biodistribution of Lanthanide(III) Complexes of Some Polyaza
Macrocyclic Acetates Containing Pyridine</article-title>. <source>Inorg.
Chem.</source>
<year>1995</year>, <volume>34</volume> (<issue>8</issue>), <fpage>2233</fpage>&#x02013;<lpage>2243</lpage>. <pub-id pub-id-type="doi">10.1021/ic00112a041</pub-id>.</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Aime</surname><given-names>S.</given-names></name>; <name><surname>Botta</surname><given-names>M.</given-names></name>; <name><surname>Crich</surname><given-names>S. G.</given-names></name>; <name><surname>Giovenzana</surname><given-names>G.</given-names></name>; <name><surname>Pagliarin</surname><given-names>R.</given-names></name>; <name><surname>Sisti</surname><given-names>M.</given-names></name>; <name><surname>Terreno</surname><given-names>E.</given-names></name>
<article-title>NMR Relaxometric Studies
of Gd(III) Complexes with Heptadentate Macrocyclic Ligands</article-title>. <source>Magn. Reson. Chem.</source>
<year>1998</year>, <volume>36</volume> (<issue>S1</issue>), <fpage>S200</fpage>&#x02013;<lpage>S208</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1097-458X(199806)36:13&#x0003c;S200::AID-OMR324&#x0003e;3.0.CO;2-H</pub-id>.</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Hao</surname><given-names>J.</given-names></name>; <name><surname>Pitrou</surname><given-names>C.</given-names></name>; <name><surname>Bourrinet</surname><given-names>P.</given-names></name>
<article-title>A Comprehensive
Overview of the Efficacy
and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS
and Body</article-title>. <source>Invest. Radiol.</source>
<year>2024</year>, <volume>59</volume> (<issue>2</issue>), <fpage>124</fpage>&#x02013;<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1097/RLI.0000000000001025</pub-id>.<pub-id pub-id-type="pmid">37812485</pub-id>
</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="book" id="cit17"><person-group person-group-type="allauthors"><name><surname>Bertini</surname><given-names>I.</given-names></name>; <name><surname>Luchinat</surname><given-names>C.</given-names></name>; <name><surname>Parigi</surname><given-names>G.</given-names></name>; <name><surname>Ravera</surname><given-names>E.</given-names></name></person-group><source>NMR of Paramagnetic Molecules:
Applications to Metallobiomolecules and Models</source>; <publisher-name>Elsevier</publisher-name>, <year>2016</year>.</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Hirschhaeuser</surname><given-names>F.</given-names></name>; <name><surname>Sattler</surname><given-names>U. G. A.</given-names></name>; <name><surname>Mueller-Klieser</surname><given-names>W.</given-names></name>
<article-title>Lactate: A Metabolic Key Player in
Cancer</article-title>. <source>Cancer Res.</source>
<year>2011</year>, <volume>71</volume> (<issue>22</issue>), <fpage>6921</fpage>&#x02013;<lpage>6925</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1457</pub-id>.<pub-id pub-id-type="pmid">22084445</pub-id>
</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="book" id="cit19"><person-group person-group-type="allauthors"><name><surname>Carlin</surname><given-names>R. L.</given-names></name></person-group><source>Magnetochemistry</source>; <publisher-name>Springer Science
&#x00026; Business Media</publisher-name>, <year>2012</year>.</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Terreno</surname><given-names>E.</given-names></name>; <name><surname>Botta</surname><given-names>M.</given-names></name>; <name><surname>Fedeli</surname><given-names>F.</given-names></name>; <name><surname>Mondino</surname><given-names>B.</given-names></name>; <name><surname>Milone</surname><given-names>L.</given-names></name>; <name><surname>Aime</surname><given-names>S.</given-names></name>
<article-title>Enantioselective Recognition between
Chiral &#x003b1;-Hydroxy&#x02013;Carboxylates
and Macrocyclic Heptadentate Lanthanide(III) Chelates</article-title>. <source>Inorg. Chem.</source>
<year>2003</year>, <volume>42</volume> (<issue>16</issue>), <fpage>4891</fpage>&#x02013;<lpage>4897</lpage>. <pub-id pub-id-type="doi">10.1021/ic034321y</pub-id>.<pub-id pub-id-type="pmid">12895112</pub-id>
</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Kansy</surname><given-names>M.</given-names></name>; <name><surname>Senner</surname><given-names>F.</given-names></name>; <name><surname>Gubernator</surname><given-names>K.</given-names></name>
<article-title>Physicochemical High Throughput Screening:
Parallel Artificial Membrane Permeation Assay in the Description of
Passive Absorption Processes</article-title>. <source>J. Med. Chem.</source>
<year>1998</year>, <volume>41</volume> (<issue>7</issue>), <fpage>1007</fpage>&#x02013;<lpage>1010</lpage>. <pub-id pub-id-type="doi">10.1021/jm970530e</pub-id>.<pub-id pub-id-type="pmid">9544199</pub-id>
</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Aime</surname><given-names>S.</given-names></name>; <name><surname>Botta</surname><given-names>M.</given-names></name>; <name><surname>Fasano</surname><given-names>M.</given-names></name>; <name><surname>Marques</surname><given-names>M. P. M.</given-names></name>; <name><surname>Geraldes</surname><given-names>C. F. G. C.</given-names></name>; <name><surname>Pubanz</surname><given-names>D.</given-names></name>; <name><surname>Merbach</surname><given-names>A. E.</given-names></name>
<article-title>Conformational
and Coordination Equilibria
on DOTA Complexes of Lanthanide Metal Ions in Aqueous Solution Studied
by 1H-NMR Spectroscopy</article-title>. <source>Inorg. Chem.</source>
<year>1997</year>, <volume>36</volume> (<issue>10</issue>), <fpage>2059</fpage>&#x02013;<lpage>2068</lpage>. <pub-id pub-id-type="doi">10.1021/ic961364o</pub-id>.<pub-id pub-id-type="pmid">11669824</pub-id>
</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="book" id="cit23"><person-group person-group-type="allauthors"><name><surname>Allinger</surname><given-names>N. L.</given-names></name>; <name><surname>Eliel</surname><given-names>E. L.</given-names></name></person-group><source>Topics in Stereochemistry</source>; <publisher-name>John
Wiley &#x00026; Sons</publisher-name>, <year>2009</year>.</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Kiefer</surname><given-names>G. E.</given-names></name>; <name><surname>Woods</surname><given-names>M.</given-names></name>
<article-title>Solid State and Solution Dynamics of Pyridine Based Tetraaza-Macrocyclic
Lanthanide Chelates Possessing Phosphonate Ligating Functionality
(Ln-PCTMB): Effect on Relaxometry and Optical Properties</article-title>. <source>Inorg. Chem.</source>
<year>2009</year>, <volume>48</volume> (<issue>24</issue>), <fpage>11767</fpage>&#x02013;<lpage>11778</lpage>. <pub-id pub-id-type="doi">10.1021/ic901779k</pub-id>.<pub-id pub-id-type="pmid">19908824</pub-id>
</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Jian</surname><given-names>Y.</given-names></name>; <name><surname>Mo</surname><given-names>G.</given-names></name>; <name><surname>Xu</surname><given-names>W.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Ding</surname><given-names>Y.</given-names></name>; <name><surname>Gao</surname><given-names>R.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Zhu</surname><given-names>J.</given-names></name>; <name><surname>Shu</surname><given-names>K.</given-names></name>; <name><surname>Yan</surname><given-names>Z.</given-names></name>; <name><surname>Carniato</surname><given-names>F.</given-names></name>; <name><surname>Platas-Iglesias</surname><given-names>C.</given-names></name>; <name><surname>Ye</surname><given-names>F.</given-names></name>; <name><surname>Botta</surname><given-names>M.</given-names></name>; <name><surname>Dai</surname><given-names>L.</given-names></name>
<article-title>Chiral Pyclen-Based Heptadentate Chelates as Highly Stable MRI Contrast
Agents</article-title>. <source>Inorg. Chem.</source>
<year>2024</year>, <volume>63</volume> (<issue>18</issue>), <fpage>8462</fpage>&#x02013;<lpage>8475</lpage>. <pub-id pub-id-type="doi">10.1021/acs.inorgchem.4c01028</pub-id>.<pub-id pub-id-type="pmid">38642052</pub-id>
</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Wu</surname><given-names>B.</given-names></name>; <name><surname>Warnock</surname><given-names>G.</given-names></name>; <name><surname>Zaiss</surname><given-names>M.</given-names></name>; <name><surname>Lin</surname><given-names>C.</given-names></name>; <name><surname>Chen</surname><given-names>M.</given-names></name>; <name><surname>Zhou</surname><given-names>Z.</given-names></name>; <name><surname>Mu</surname><given-names>L.</given-names></name>; <name><surname>Nanz</surname><given-names>D.</given-names></name>; <name><surname>Tuura</surname><given-names>R.</given-names></name>; <name><surname>Delso</surname><given-names>G.</given-names></name>
<article-title>An Overview of CEST MRI for Non-MR
Physicists</article-title>. <source>EJNMMI Phys.</source>
<year>2016</year>, <volume>3</volume> (<issue>1</issue>), <fpage>19</fpage><pub-id pub-id-type="doi">10.1186/s40658-016-0155-2</pub-id>.<pub-id pub-id-type="pmid">27562024</pub-id>
</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Soesbe</surname><given-names>T. C.</given-names></name>; <name><surname>Wu</surname><given-names>Y.</given-names></name>; <name><surname>Dean Sherry</surname><given-names>A.</given-names></name>
<article-title>Advantages
of Paramagnetic Chemical Exchange Saturation
Transfer (CEST) Complexes Having Slow to Intermediate Water Exchange
Properties as Responsive MRI Agents</article-title>. <source>NMR Biomed.</source>
<year>2013</year>, <volume>26</volume> (<issue>7</issue>), <fpage>829</fpage>&#x02013;<lpage>838</lpage>. <pub-id pub-id-type="doi">10.1002/nbm.2874</pub-id>.<pub-id pub-id-type="pmid">23055299</pub-id>
</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Kumas</surname><given-names>C.</given-names></name>; <name><surname>Fernando</surname><given-names>W. S.</given-names></name>; <name><surname>Zhao</surname><given-names>P.</given-names></name>; <name><surname>Regueiro-Figueroa</surname><given-names>M.</given-names></name>; <name><surname>Kiefer</surname><given-names>G. E.</given-names></name>; <name><surname>Martins</surname><given-names>A. F.</given-names></name>; <name><surname>Platas-Iglesias</surname><given-names>C.</given-names></name>; <name><surname>Sherry</surname><given-names>A. D.</given-names></name>
<article-title>Unexpected Changes in the Population of Coordination
Isomers for the Lanthanide Ion Complexes of DOTMA&#x02013;Tetraglycinate</article-title>. <source>Inorg. Chem.</source>
<year>2016</year>, <volume>55</volume> (<issue>18</issue>), <fpage>9297</fpage>&#x02013;<lpage>9305</lpage>. <pub-id pub-id-type="doi">10.1021/acs.inorgchem.6b01390</pub-id>.<pub-id pub-id-type="pmid">27603690</pub-id>
</mixed-citation></ref><ref id="ref100"><mixed-citation publication-type="journal" id="cit100"><name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Martins</surname><given-names>A. F.</given-names></name>; <name><surname>Zhao</surname><given-names>P.</given-names></name>; <name><surname>Tieu</surname><given-names>M.</given-names></name>; <name><surname>Esteban-G&#x000f3;mez</surname><given-names>D.</given-names></name>; <name><surname>McCandless</surname><given-names>G. T.</given-names></name>; <name><surname>Platas-Iglesias</surname><given-names>C.</given-names></name>; <name><surname>Sherry</surname><given-names>A. D.</given-names></name>
<article-title>Enantiomeric Recognition of D- and l-Lactate by CEST
with the Aid of a Paramagnetic Shift Reagent</article-title>. <source>J. Am. Chem. Soc.</source>
<year>2017</year>, <volume>139</volume> (<issue>48</issue>), <fpage>17431</fpage>&#x02013;<lpage>17437</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.7b08292</pub-id>.<pub-id pub-id-type="pmid">29083166</pub-id>
</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Zaiss</surname><given-names>M.</given-names></name>; <name><surname>Jin</surname><given-names>T.</given-names></name>; <name><surname>Kim</surname><given-names>S.-G.</given-names></name>; <name><surname>Gochberg</surname><given-names>D. F.</given-names></name>
<article-title>Theory of Chemical Exchange Saturation
Transfer MRI in the Context of Different Magnetic Fields</article-title>. <source>NMR Biomed.</source>
<year>2022</year>, <volume>35</volume> (<issue>11</issue>), <elocation-id>e4789</elocation-id><pub-id pub-id-type="doi">10.1002/nbm.4789</pub-id>.<pub-id pub-id-type="pmid">35704180</pub-id>
</mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Castro</surname><given-names>G.</given-names></name>; <name><surname>Regueiro-Figueroa</surname><given-names>M.</given-names></name>; <name><surname>Esteban-G&#x000f3;mez</surname><given-names>D.</given-names></name>; <name><surname>Bastida</surname><given-names>R.</given-names></name>; <name><surname>Mac&#x000ed;as</surname><given-names>A.</given-names></name>; <name><surname>P&#x000e9;rez-Lourido</surname><given-names>P.</given-names></name>; <name><surname>Platas-Iglesias</surname><given-names>C.</given-names></name>; <name><surname>Valencia</surname><given-names>L.</given-names></name>
<article-title>Exceptionally Inert Lanthanide(III) PARACEST MRI Contrast
Agents Based on an 18-Membered Macrocyclic Platform</article-title>. <source>Chem.&#x02014;Eur. J.</source>
<year>2015</year>, <volume>21</volume> (<issue>51</issue>), <fpage>18662</fpage>&#x02013;<lpage>18670</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201502937</pub-id>.<pub-id pub-id-type="pmid">26538320</pub-id>
</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Dixon</surname><given-names>W. T.</given-names></name>; <name><surname>Ren</surname><given-names>J.</given-names></name>; <name><surname>Lubag</surname><given-names>A. J. M.</given-names></name>; <name><surname>Ratnakar</surname><given-names>J.</given-names></name>; <name><surname>Vinogradov</surname><given-names>E.</given-names></name>; <name><surname>Hancu</surname><given-names>I.</given-names></name>; <name><surname>Lenkinski</surname><given-names>R. E.</given-names></name>; <name><surname>Sherry</surname><given-names>A. D.</given-names></name>
<article-title>A Concentration-Independent
Method to Measure Exchange Rates in PARACEST Agents</article-title>. <source>Magn. Reson. Med.</source>
<year>2010</year>, <volume>63</volume> (<issue>3</issue>), <fpage>625</fpage>&#x02013;<lpage>632</lpage>. <pub-id pub-id-type="doi">10.1002/mrm.22242</pub-id>.<pub-id pub-id-type="pmid">20187174</pub-id>
</mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Lee</surname><given-names>J.-S.</given-names></name>; <name><surname>Regatte</surname><given-names>R. R.</given-names></name>; <name><surname>Jerschow</surname><given-names>A.</given-names></name>
<article-title>Bloch Equations for Proton Exchange
Reactions in an Aqueous Solution</article-title>. <source>Concepts Magn.
Reson. Part A</source>
<year>2016</year>, <volume>45A</volume> (<issue>3</issue>), <elocation-id>e21397</elocation-id><pub-id pub-id-type="doi">10.1002/cmr.a.21397</pub-id>.</mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Vassallo</surname><given-names>G.</given-names></name>; <name><surname>Garello</surname><given-names>F.</given-names></name>; <name><surname>Aime</surname><given-names>S.</given-names></name>; <name><surname>Terreno</surname><given-names>E.</given-names></name>; <name><surname>Delli Castelli</surname><given-names>D.</given-names></name>
<article-title>31P ParaCEST:
31P MRI-CEST Imaging Based on the Formation of a Ternary Adduct between
Inorganic Phosphate and Eu-DO3A</article-title>. <source>Inorg. Chem.</source>
<year>2022</year>, <volume>61</volume> (<issue>49</issue>), <fpage>19663</fpage>&#x02013;<lpage>19667</lpage>. <pub-id pub-id-type="doi">10.1021/acs.inorgchem.2c03329</pub-id>.<pub-id pub-id-type="pmid">36445702</pub-id>
</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Gao</surname><given-names>S.</given-names></name>; <name><surname>Chen</surname><given-names>M.-L.</given-names></name>; <name><surname>Zhou</surname><given-names>Z.-H.</given-names></name>
<article-title>Substitution
of Gadolinium Ethylenediaminetetraacetate
with Phosphites: Towards Gadolinium Deposit in Nephrogenic Systemic
Fibrosis</article-title>. <source>Dalton Trans.</source>
<year>2014</year>, <volume>43</volume> (<issue>2</issue>), <fpage>639</fpage>&#x02013;<lpage>645</lpage>. <pub-id pub-id-type="doi">10.1039/C3DT52015C</pub-id>.<pub-id pub-id-type="pmid">24132302</pub-id>
</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Yamazaki</surname><given-names>Y.</given-names></name>; <name><surname>Imura</surname><given-names>A.</given-names></name>; <name><surname>Urakawa</surname><given-names>I.</given-names></name>; <name><surname>Shimada</surname><given-names>T.</given-names></name>; <name><surname>Murakami</surname><given-names>J.</given-names></name>; <name><surname>Aono</surname><given-names>Y.</given-names></name>; <name><surname>Hasegawa</surname><given-names>H.</given-names></name>; <name><surname>Yamashita</surname><given-names>T.</given-names></name>; <name><surname>Nakatani</surname><given-names>K.</given-names></name>; <name><surname>Saito</surname><given-names>Y.</given-names></name>; <name><surname>Okamoto</surname><given-names>N.</given-names></name>; <name><surname>Kurumatani</surname><given-names>N.</given-names></name>; <name><surname>Namba</surname><given-names>N.</given-names></name>; <name><surname>Kitaoka</surname><given-names>T.</given-names></name>; <name><surname>Ozono</surname><given-names>K.</given-names></name>; <name><surname>Sakai</surname><given-names>T.</given-names></name>; <name><surname>Hataya</surname><given-names>H.</given-names></name>; <name><surname>Ichikawa</surname><given-names>S.</given-names></name>; <name><surname>Imel</surname><given-names>E. A.</given-names></name>; <name><surname>Econs</surname><given-names>M. J.</given-names></name>; <name><surname>Nabeshima</surname><given-names>Y.-I.</given-names></name>
<article-title>Establishment of Sandwich ELISA for Soluble Alpha-Klotho
Measurement: Age-Dependent Change of Soluble Alpha-Klotho Levels in
Healthy Subjects</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<year>2010</year>, <volume>398</volume> (<issue>3</issue>), <fpage>513</fpage>&#x02013;<lpage>518</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2010.06.110</pub-id>.<pub-id pub-id-type="pmid">20599764</pub-id>
</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Papaloucas</surname><given-names>C. D.</given-names></name>; <name><surname>Papaloucas</surname><given-names>M. D.</given-names></name>; <name><surname>Kouloulias</surname><given-names>V.</given-names></name>; <name><surname>Neanidis</surname><given-names>K.</given-names></name>; <name><surname>Pistevou-Gompaki</surname><given-names>K.</given-names></name>; <name><surname>Kouvaris</surname><given-names>J.</given-names></name>; <name><surname>Zygogianni</surname><given-names>A.</given-names></name>; <name><surname>Mystakidou</surname><given-names>K.</given-names></name>; <name><surname>Papaloucas</surname><given-names>A. C.</given-names></name>
<article-title>Measurement of Blood Phosphorus: A Quick and Inexpensive
Method for Detection of the Existence of Cancer in the Body. Too Good
to Be True, or Forgotten Knowledge of the Past?</article-title>. <source>Med. Hypotheses</source>
<year>2014</year>, <volume>82</volume> (<issue>1</issue>), <fpage>24</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.mehy.2013.10.028</pub-id>.<pub-id pub-id-type="pmid">24252275</pub-id>
</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Bobko</surname><given-names>A. A.</given-names></name>; <name><surname>Eubank</surname><given-names>T. D.</given-names></name>; <name><surname>Driesschaert</surname><given-names>B.</given-names></name>; <name><surname>Dhimitruka</surname><given-names>I.</given-names></name>; <name><surname>Evans</surname><given-names>J.</given-names></name>; <name><surname>Mohammad</surname><given-names>R.</given-names></name>; <name><surname>Tchekneva</surname><given-names>E. E.</given-names></name>; <name><surname>Dikov</surname><given-names>M. M.</given-names></name>; <name><surname>Khramtsov</surname><given-names>V. V.</given-names></name>
<article-title>Interstitial Inorganic Phosphate
as a Tumor Microenvironment Marker for Tumor Progression</article-title>. <source>Sci. Rep.</source>
<year>2017</year>, <volume>7</volume> (<issue>1</issue>), <fpage>41233</fpage><pub-id pub-id-type="doi">10.1038/srep41233</pub-id>.<pub-id pub-id-type="pmid">28117423</pub-id>
</mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Lacerda-Abreu</surname><given-names>M. A.</given-names></name>; <name><surname>Meyer-Fernandes</surname><given-names>J. R.</given-names></name>
<article-title>Inorganic
Phosphate (Pi) in the Breast Cancer Microenvironment:
Production,Transport and Signal Transduction as Potential Targets
for AnticancerStrategies</article-title>. <source>Curr. Cancer Drug
Targets</source>
<year>2023</year>, <volume>23</volume> (<issue>3</issue>), <fpage>187</fpage>&#x02013;<lpage>198</lpage>. <pub-id pub-id-type="doi">10.2174/1568009622666220928140702</pub-id>.<pub-id pub-id-type="pmid">36173081</pub-id>
</mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Lee</surname><given-names>S.-C.</given-names></name>; <name><surname>Huang</surname><given-names>M. Q.</given-names></name>; <name><surname>Nelson</surname><given-names>D. S.</given-names></name>; <name><surname>Pickup</surname><given-names>S.</given-names></name>; <name><surname>Wehrli</surname><given-names>S.</given-names></name>; <name><surname>Adegbola</surname><given-names>O.</given-names></name>; <name><surname>Poptani</surname><given-names>H.</given-names></name>; <name><surname>Delikatny</surname><given-names>E. J.</given-names></name>; <name><surname>Glickson</surname><given-names>J. D.</given-names></name>
<article-title>In vivo MRS markers of response to
CHOP chemotherapy
in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft</article-title>. <source>NMR Biomed.</source>
<year>2008</year>, <volume>21</volume> (<issue>7</issue>), <fpage>723</fpage>&#x02013;<lpage>733</lpage>. <pub-id pub-id-type="doi">10.1002/nbm.1250</pub-id>.<pub-id pub-id-type="pmid">18384181</pub-id>
</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Brizel</surname><given-names>D. M.</given-names></name>; <name><surname>Schroeder</surname><given-names>T.</given-names></name>; <name><surname>Scher</surname><given-names>R. L.</given-names></name>; <name><surname>Walenta</surname><given-names>S.</given-names></name>; <name><surname>Clough</surname><given-names>R. W.</given-names></name>; <name><surname>Dewhirst</surname><given-names>M. W.</given-names></name>; <name><surname>Mueller-Klieser</surname><given-names>W.</given-names></name>
<article-title>Elevated Tumor Lactate Concentrations
Predict for an Increased Risk of Metastases in Head-and-Neck Cancer</article-title>. <source>Int. J. Radiat. Oncol.</source>
<year>2001</year>, <volume>51</volume> (<issue>2</issue>), <fpage>349</fpage>&#x02013;<lpage>353</lpage>. <pub-id pub-id-type="doi">10.1016/S0360-3016(01)01630-3</pub-id>.</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Roy</surname><given-names>L. E.</given-names></name>; <name><surname>Martin</surname><given-names>L.R.</given-names></name>; <name><surname>Theoretical</surname><given-names>L.</given-names></name>
<article-title>Prediction
of Coordination Environments
and Stability Constants of Lanthanum Lactate Complexes in Solution</article-title>. <source>Dalton Trans.</source>
<year>2016</year>, <volume>45</volume> (<issue>39</issue>), <fpage>15517</fpage>&#x02013;<lpage>15522</lpage>. <pub-id pub-id-type="doi">10.1039/C5DT03385C</pub-id>.<pub-id pub-id-type="pmid">27704061</pub-id>
</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Botta</surname><given-names>M.</given-names></name>; <name><surname>Aime</surname><given-names>S.</given-names></name>; <name><surname>Barge</surname><given-names>A.</given-names></name>; <name><surname>Bobba</surname><given-names>G.</given-names></name>; <name><surname>Dickins</surname><given-names>R. S.</given-names></name>; <name><surname>Parker</surname><given-names>D.</given-names></name>; <name><surname>Terreno</surname><given-names>E.</given-names></name>
<article-title>Ternary Complexes between Cationic
GdIII Chelates and Anionic Metabolites in Aqueous Solution: An NMR
Relaxometric Study</article-title>. <source>Chem.&#x02014;Eur. J.</source>
<year>2003</year>, <volume>9</volume> (<issue>9</issue>), <fpage>2102</fpage>&#x02013;<lpage>2109</lpage>. <pub-id pub-id-type="doi">10.1002/chem.200204475</pub-id>.<pub-id pub-id-type="pmid">12740859</pub-id>
</mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Pal</surname><given-names>R.</given-names></name>; <name><surname>Parker</surname><given-names>D.</given-names></name>; <name><surname>Costello</surname><given-names>L. C.</given-names></name>
<article-title>A Europium
Luminescence Assay of
Lactate and Citrate in Biological Fluids</article-title>. <source>Org.
Biomol. Chem.</source>
<year>2009</year>, <volume>7</volume> (<issue>8</issue>), <fpage>1525</fpage>&#x02013;<lpage>1528</lpage>. <pub-id pub-id-type="doi">10.1039/b901251f</pub-id>.<pub-id pub-id-type="pmid">19343236</pub-id>
</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Liu</surname><given-names>G.</given-names></name>; <name><surname>Ali</surname><given-names>M. M.</given-names></name>; <name><surname>Yoo</surname><given-names>B.</given-names></name>; <name><surname>Griswold</surname><given-names>M. A.</given-names></name>; <name><surname>Tkach</surname><given-names>J. A.</given-names></name>; <name><surname>Pagel</surname><given-names>M. D.</given-names></name>
<article-title>PARACEST MRI with
Improved Temporal Resolution</article-title>. <source>Magn. Reson. Med.</source>
<year>2009</year>, <volume>61</volume> (<issue>2</issue>), <fpage>399</fpage>&#x02013;<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1002/mrm.21863</pub-id>.<pub-id pub-id-type="pmid">19165903</pub-id>
</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Han</surname><given-names>Z.</given-names></name>; <name><surname>Chen</surname><given-names>C.</given-names></name>; <name><surname>Xu</surname><given-names>X.</given-names></name>; <name><surname>Bai</surname><given-names>R.</given-names></name>; <name><surname>Staedtke</surname><given-names>V.</given-names></name>; <name><surname>Huang</surname><given-names>J.</given-names></name>; <name><surname>Chan</surname><given-names>K. W. Y.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Kamson</surname><given-names>D. O.</given-names></name>; <name><surname>Wen</surname><given-names>Z.</given-names></name>; <name><surname>Knutsson</surname><given-names>L.</given-names></name>; <name><surname>van Zijl</surname><given-names>P. C. M.</given-names></name>; <name><surname>Liu</surname><given-names>G.</given-names></name>
<article-title>Dynamic Contrast-Enhanced
CEST MRI Using a Low Molecular Weight Dextran</article-title>. <source>NMR Biomed.</source>
<year>2022</year>, <volume>35</volume> (<issue>3</issue>), <elocation-id>e4649</elocation-id><pub-id pub-id-type="doi">10.1002/nbm.4649</pub-id>.<pub-id pub-id-type="pmid">34779550</pub-id>
</mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Klein</surname><given-names>S.</given-names></name>; <name><surname>Staring</surname><given-names>M.</given-names></name>; <name><surname>Murphy</surname><given-names>K.</given-names></name>; <name><surname>Viergever</surname><given-names>M. A.</given-names></name>; <name><surname>Pluim</surname><given-names>J. P. W.</given-names></name>
<article-title>Elastix: A Toolbox for Intensity-Based
Medical Image
Registration</article-title>. <source>IEEE Trans. Med. Imaging</source>
<year>2010</year>, <volume>29</volume> (<issue>1</issue>), <fpage>196</fpage>&#x02013;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1109/TMI.2009.2035616</pub-id>.<pub-id pub-id-type="pmid">19923044</pub-id>
</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Mueller</surname><given-names>S.</given-names></name>; <name><surname>Stirnberg</surname><given-names>R.</given-names></name>; <name><surname>Akbey</surname><given-names>S.</given-names></name>; <name><surname>Ehses</surname><given-names>P.</given-names></name>; <name><surname>Scheffler</surname><given-names>K.</given-names></name>; <name><surname>St&#x000f6;cker</surname><given-names>T.</given-names></name>; <name><surname>Zaiss</surname><given-names>M.</given-names></name>
<article-title>Whole Brain Snapshot CEST at 3T Using
3D-EPI: Aiming for Speed, Volume, and Homogeneity</article-title>. <source>Magn. Reson. Med.</source>
<year>2020</year>, <volume>84</volume> (<issue>5</issue>), <fpage>2469</fpage>&#x02013;<lpage>2483</lpage>. <pub-id pub-id-type="doi">10.1002/mrm.28298</pub-id>.<pub-id pub-id-type="pmid">32385888</pub-id>
</mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="computer-program" id="cit48"><source>ChemAxon - Software for Chemistry and Biology R&#x00026;D</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.chemaxon.com/">https://www.chemaxon.com/</uri> (accessed
2017-04-26).</mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name><surname>Chu</surname><given-names>K.-C.</given-names></name>; <name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Balschi</surname><given-names>J. A.</given-names></name>; <name><surname>Springer</surname><given-names>C. S.</given-names><suffix>Jr</suffix></name>
<article-title>Bulk Magnetic
Susceptibility Shifts in Nmr Studies of Compartmentalized Samples:
Use of Paramagnetic Reagents</article-title>. <source>Magn. Reson. Med.</source>
<year>1990</year>, <volume>13</volume> (<issue>2</issue>), <fpage>239</fpage>&#x02013;<lpage>262</lpage>. <pub-id pub-id-type="doi">10.1002/mrm.1910130207</pub-id>.<pub-id pub-id-type="pmid">2156125</pub-id>
</mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name><surname>Sheth</surname><given-names>V. R.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>L. Q.</given-names></name>; <name><surname>Howison</surname><given-names>C. M.</given-names></name>; <name><surname>Flask</surname><given-names>C. A.</given-names></name>; <name><surname>Pagel</surname><given-names>M. D.</given-names></name>
<article-title>Measuring
in Vivo Tumor pHe with CEST-FISP MRI</article-title>. <source>Magn.
Reson. Med.</source>
<year>2012</year>, <volume>67</volume> (<issue>3</issue>), <fpage>760</fpage>&#x02013;<lpage>768</lpage>. <pub-id pub-id-type="doi">10.1002/mrm.23038</pub-id>.<pub-id pub-id-type="pmid">22028287</pub-id>
</mixed-citation></ref></ref-list></back></article>